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In 1996, South Africa adopted a National Drugs Policy.  An important objective of this policy 
focused on promoting the use of generic medicines in the country to ensure that medicines 
are accessible to the majority of South Africans. Pharmacists play a vital role in influencing 
patients’ choice of medication, thus highlighting the importance of gaining all health 
professionals’ support for the quality and utilization of generic medicines. 
OBJECTIVES 
This study sought to assess and evaluate the perceptions, views, knowledge and willingness 
to recommend generic medicines by pharmacists that are located within the Western Cape, as 
well as to explore pharmacists’ perceptions towards the safety, quality, and efficacy of 
generic medicines. In addition, the study assessed pharmacists’ views on current policy with 
respect to substitution of generic medicines as well as to determine if these views vary in the 
different practice settings. Finally the study assessed pharmacists’ views on the pricing 
system of generics as well as their opinion on promotion of these medications. 
METHOD 
A cross-sectional online survey, which targeted 1730 pharmacists living in the Western Cape, 
was conducted, using SurveyMonkey, from 7 September to 7 October 2014. Data collected 
included participant demographics, qualification, experience, education, knowledge and 
perceptions of generic medication. Survey Monkey was used to produce graphical 
representations of the data and data was exported onto Microsoft excel in order to make 
analytical comparisons. 
RESULTS 
A total of 321 pharmacists responded to the questionnaire (a response rate of 18,6%). 82% of 
pharmacists stated there is no difference in safety between original brand and generic 
medicines. Majority of respondents (74%) believed that generic medicines are therapeutically 
equivalent to the original medicines. However, 39% of pharmacists stated that original 
medicines are of a better quality than their generic counterparts. A large number (more than 
60%) of pharmacists reported concerns of bioequivalence as their main problem when 
switching to a generic medicine. 
 10 
CONCLUSION 
Majority of Pharmacists in the Western Cape had a positive outlook on generic medication 
and supported and encouraged its use. Concerns were raised however, regarding quality, 
safety, and effectiveness of generic medicines as well as doubts in the reliability of certain 
generic manufacturing companies. Pharmacists’ opinions could negatively impact generic 
usage in South Africa, therefore continuing education and awareness campaigns should be 
implemented in order to re-confirm pharmacists’ knowledge of generic medicines being 
bioequivalent and of equal quality to branded medicines. Furthermore, pharmacists should be 
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INTRODUCTION AND BACKGROUND 
 
1.1 Importance of medicines in Healthcare 
Medicines are a crucial component of healthcare. Making it easily accessible and cost 
effective for the population however, is an on-going challenge. Medicines play an important 
role in managing the health needs of a population, particularly with regard to the care of 
chronic diseases, the provision of preventive care services such as immunisation and family 
planning, as well as health education. (1) It is therefore important to ensure the availability and 
accessibility of affordable quality medicines to all segments of the society. A primary health 
care system without medicines is, however, like a river without water. (1) 
Households in Africa have insufficient access to essential medicines. Barriers to access that 
have been identified are as follows:  
 The ex-manufacturer price influences access. This can best be addressed through 
regulating the price of medicines along the supply chain. (2) 
 Inefficiencies in the supply and distribution chain. A tracking system to assess the 
availability of medicines through the medicine supply chain should be implemented. 
(2) 
 A simplified, universal, and transparent regulatory approval process particularly for 
generic medicines that is efficient. (2) 
 An effectively implemented generic substitution policy. (2) 
Measures should be taken in order to ensure that all citizens are provided with safe, quality 
and efficacious essential medicines. 
 
1.2 South Africa’s Healthcare system 
Health care in South Africa ranges from the most basic primary health care services, offered 
freely by the State, to highly specialised, hi-tech health tertiary healthcare services that are 
available in both the public and private sector. (3) The public sector is however, financially 
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overburdened and critically under-resourced in several areas. Despite approximately 40% of 
all government expenditure being directed toward healthcare, the public health sector still 
remains under pressure to deliver services to essentially 80% of the population. (3) 
In 2011, total health expenditure was R248.6-billion, approximately 8,3% of GDP, which 
was, above the 5% recommended by the World Health Organisation (WHO) and relatively 
high by international standards. Despite this high expenditure, health outcomes remain poor 
in comparison to similar middle-income countries. (3) This forms a strong argument so that 
the challenge facing the South African health system is efficient and equitable use of 













1.3 South Africa and generic medicines 
The cost of medical care is increasing rapidly, making healthcare unaffordable for an 
increasing proportion of South Africa’s population. (5) As access to healthcare increases, there 
is greater demand for medicines in the country. (5) One way to reduce the cost of medication 
Figure 1: Map of Health Services in South Africa 
(World health organisation, May 2003) 
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without affecting the quality of medical care is to substitute the original (branded) products 
with generic medication. (6)  
In 1996, South Africa adopted a National Drugs Policy, and an important objective of this 
policy focused on promoting the use of generic medicines in the country. The policy states: 
“It will be incumbent on the pharmacist, prior to dispensing a prescription, to inform the 
patient on the benefits of generic substitution and to ensure that substitution takes place with 
the patient’s full understanding and consent”. (7) The intention of this policy is to increase the 
accessibility of affordable healthcare to the majority of people living in South Africa.  
Generic medicine usage in South Africa however, still remains low with an evaluation 
released by the National Association of Pharmaceutical Manufacturers (NAPM) revealing 
that only 20% of South African prescriptions are made up of generic medicines. (3)According 
to comments by the chairman of the organisation, Muhammed Bodhania, ‘’there has only 
been a 1% increase in the use of generics from a value perspective over the last five years, 
while the increase in the total cost of medicines has increased substantially more than that’’ 
(3), He suggests that legislative changes be made in order to allow manufacturing companies 
to launch generic medicines into the market as soon as the original medicine patent expires. 
By increasing the availability and utilisation of generic medicines, NAPM estimates al almost 
R24 billion saving for the country. (3) 
The MCC should also focus more attention on ridding the market of medicines illegitimately 
marketed from foreign countries. This is important to prevent sub-standard medicines from 
being sold. Medicines imported from internationally recognised companies should be 
registered as soon as possible and post market surveillance implemented in order to ensure 
that medicines are efficacious and safe.    
 
1.4 Pharmacists and generic substitution 
The role of the pharmacist has been changing over the past two decades, as they are now an 
integral team member in the provision of health care. For pharmacists, their greater 
involvement in medication selection means greater responsibility towards their customers and 
an increased need for accountability. (8) Pharmacists are the key role-players in generic 
substitution as they are the most likely health care professional to interact with patients 
regarding use and safety of medicines. Generally, patients want reassurance from the 
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pharmacist that the generic medicine is as good as the brand name medicine when they get 
substituted. As trusted health care professionals and having the requisite education, 
pharmacists are in the perfect position to provide time, reassurance and advice about 
medication. (9) 
Patient counselling by pharmacists is of vital importance in empowering consumers to make 
informed decisions about their medical treatments and take responsibility for their own 
health. (10) Adequate counselling by pharmacists will improve communication between 
patients and health care providers and aid and encourage effective use of medicines so that 
patients see the pharmacist as more than just dispensers of medication but as advisers and 
consultants that are experts in providing medicine related education and ensuring rational and 
effective medication usage. (11) The pharmacists need to be more active in counselling 
patients when there is a change in the patients’ prescription (change from brand name to 
generic medication, change of manufacturer, etc.). Pharmacists are an important information 
source and thus should provide patients with the information necessary to reduce existing 
patient confusion about generic medicines. It has been determined in various studies that 
pharmacists are a profession that patients have confidence in. (12) It is likely that if 
pharmacists are confident about generic medicines, then they are likely to convince patients 
to swop to generic medicines with greater reassurance. 
With the advent of the mandatory requirement of the offer of generic substitution in South 
Africa by pharmacists, it is imperative to investigate the knowledge, views and perceptions of 
pharmacists in the country with regards to generic medicines, in order to assess if they are 
enabling the implementation of the policy. 
 
1.5 Study objectives 
 
1) To assess the perceptions of generic medicines of pharmacists who are located within 
the Western Cape Region 
2) To evaluate these pharmacists' perceptions (based on their observation), views (based 
on their biased opinions), knowledge of and willingness to recommend generic 
medicines. 
3) To explore these pharmacists perceptions of the safety, quality, and efficacy of 
generic medicines. 
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4) To assess these pharmacists' views on current policy with respect to substitution of 
generic medicines. 
5) To assess these pharmacists’ views on the pricing system of generics as well as their 
opinion on promotion of these medications 
6) To determine if views in the different practice settings vary.  
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CHAPTER 2: LITERATURE REVIEW 
The focus of the literature review is on definition of terms as well as other studies undertaken 
with regards to the implementation of generic prescribing and generic substitution within the 
pharmaceutical environment in South Africa and internationally. 
 
2.1 Definition of generic medicines 
Generic medicines have been used extensively for decades and are comparable versions of 
brand-name medicines. (13) The active pharmaceutical ingredient in a generic medicine and its 
branded counterpart are chemically identical, generic medicines typically cost far less than 
brand-name medicines because of smaller start up costs. (14)  Generic medicines have the 
same strength, dosage form, and route of administration as the brand name medicine, but do 
not need to contain the same inactive ingredients. (15) 
 
2.2 Safety Standards  
In order for a generic medicine to be approved, generic medicine manufacturers must prove 
that their medication is bioequivalent to the brand name or originator medicine. In South 
Africa, it must meet rigorous standards established by the Medicines Control Council (MCC), 
which is the regulatory body that reviews the bioequivalence data, thus ensuring that the 
generic medicine performs the same as its respective brand name medicine, whether as an 
immediate or controlled release dosage form. The MCC also has stringent regulations with 
regards to identity, strength, quality, purity, and potency of the medication. Some variation in 
purity, size, strength and other parameters can and does occur during manufacturing for all 
medicines, however, the MCC limits how much variability is acceptable. (15)  
All generic manufacturing, packaging, and testing sites have to pass the same quality 
standards as those of brand name medicines, and the former must meet the same 
specifications as any brand name product. In fact, many generic medicines are made in the 




2.3 Bioequivalence studies in South Africa 
In order for a generic medicine to be approved by the MCC it must prove to be bioequivalent 
to its original counterpart. Bioequivalence studies ensure that both medications have 
equivalent bioavailability. This means that the rate and extent of absorption of active 
ingredients or active metabolites from a product into the systemic circulation between the two 
medications must be similar.  
In South Africa the following are needed for registration (16) : 
 “Bioavailability e.g. serum levels are needed 
 Testing generic in vitro activity against known laboratory strains i.e. MIC, MBC, 
Time-kill curves and SMR after exposure  
 Testing in vivo activity in animal models and even in humans  
 Shelf–life: Random sampling and monitoring –post marketing surveillance”  
A study by Walker et al (2006) researched the South African approach toward the assessment 
of generic medicines. (17) Various bioequivalence issues have been recently addressed in order 
to ensure that all medications are of the highest safety, efficacy and quality. Important issues 
addressed included the criteria for acceptance and recommended bioequivalence intervals, as 
well as the use of a foreign reference product and the process of assessing highly variable 
medicines. In addition, the use of “old” bio-studies submitted in support of an application is 
subject to expiry date. (17) 
 - In Vitro Testing 
In vitro testing in South Africa is an integral component to ensure medicine safety and 
quality.  In 2005, Liebowitz L et al compared the in vitro activity of Aspens generic 
injectable cephalosporins to that of the original medicines. It was noted that the MIC values 
of the generic and original medicines were comparable. (16) However, testing has also 
revealed unfavourable results in some cases. 
Two combination generic Tuberculosis medicines, called Ebsar and Antib - 4 that were 
manufactured in India and registered in South Africa were removed from the market in 2008 
after in-vitro testing revealed that the medicines contained subtherapeutic quantities of two of 
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the active ingredients. These tests were important as concerns were raised regarding possible 
TB medicine resistance. (16)  
2.4 International bioequivelance studies 
Numerous studies have been conducted internationally, assessing the bioequivelance between 
generic and original medicines. A study by Bobo et al (2010) reviewed the effectiveness and 
tolerability of 966 patients that were swopped from original to generic clozapine. (18) Most of 
the patients tolerated the switch without any worsening of symptoms or adverse effects.There 
was no increased intensive service utilization, or adjustments to medication. (18) Current 
evidence indicates that the effectiveness and safety of generic clozapine formulations in 
patients who were previously on brand-name clozapine is the same. There is a very low risk 
of poor outcome after switching to a generic clozapine formulation appears but this is 
difficult to predict. (18) 
A study, conducted by Borgheini (2003), presented data that compared the bioequivalence 
and therapeutic efficacy of original psychoactive medicines with those of the corresponding 
generic products. (19)  Results indicated that plasma levels of phenytoin were reduced to 31% 
after a switching from a brand-name to a generic product. In addition, some studies 
(controlled) of carbamazepine indicated that there was a recurrence of convulsions after 
switching to a generic formulation. (19) Finally, an investigation by the US Food and Drug 
Administration with regards to the recurrence of seizures when generic valproic acid was 
switched for a brand-name product determined that there was a difference in bioavailability 
between the two medicines. (19) 
 - In Vitro Testing 
Lambert (2003) compared the pharmaceutical quality of 34 ceftriaxone generic products with 
Rocephin as the reference standard. (20) It was found that 18 quality standards from the 
European and US Pharmacopoeias were violated. These included violations on sterility and 
impurities, with 88% of products failing to meet clarity standards and 15% failing to achieve 
the claimed assay content. All 34 generics failed to meet Roche specifications for Rocephin.  
(20) 
A study by Nightingale (2005) compared the quality of 65 generic clarithromycin products 
manufactured in 18 countries with that of the original medicine. (21) The results demonstrated 
 20 
that the generic medicines were not comparable in vitro to that of the original medicine. Nine 
percent of the generic medicines failed to contain between 95 – 105% clarithromycin claimed 
on the label. About 34% released less active ingredient than the original and 19% of generics 
exceeded the 3% limit for impurities. (21) A similar study by the same author was conducted 
in 2000 in Latin America, Asia, Africa and Pacific regions assessing 40 different 
clarithromycin products. These results revealed that 20% of generics failed to contain the 
labelled amount of medicine, 70% released less medicine than the original and 60% exceeded 
the impurity limit. (22) The level of impurities may reflect the quality of manufacturing 
practises used in preparing new medicines, and are thus indicative of good manufacturing 
practises. (21) 
Bioequivalence studies are an important aspect of medicine research in order to confirm 
results relating to efficacy and safety of medicines conducted in clinical trials. These tests 
however should continue to be reviewed after the medicine becomes available to the market 
as problems can arise later. An example of this occurred in November 2004 whereby 
Ranbaxy withdrew all its antiretrovirals post approval. This was due to discrepancies found 
in the documentation relating to proof of the products bioequivalence with the original 
medicine. (16)  
 
2.5 Generic substitution policy in South Africa 
Generic substitution involves professional intervention by the pharmacist through: 
• Assessment of whether or not it is advisable for the patient to substitute the prescribed 
medicine with that of a generic product. (23) 
 Making a selection of the most suitable generic medicinal product. (23) 
 
The Medicines and Related Substances Act (as amended) only permits generic substitution 
within the criteria set by the section 22F (24):  
 “Pharmacists must inform patients with a prescription for dispensing, of the 
benefits of the substitution; 
 When substitution has taken place, the pharmacist must take reasonable steps to 
inform the prescriber of such substitution; and 
 Pharmacists may dispense the generic instead of the medicine prescribed, unless: 
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o  expressly forbidden by the patient to do so; 
o  the prescriber has written in his or her own hand on the prescription the 
words “no substitution” next to the item prescribed; 
o  the retail price of the generic is higher than that of the prescribed 
medicine;  
o  The product has been declared not substitutable by the MCC”. 
 
The MCC guidelines for South Africa prohibits the substitution of medications in a few 
instances, these are: 
 Agents with a narrow therapeutic range 
 Agents known to have erratic intra and inter – patient responses 
 If the medication is likely to give significant bioavailability problems 
 If the patient is critically ill, geriatric or elderly 
 
2.6 Pricing of generic medicines in South Africa 
The cost of medicines is rapidly escalating in South Africa and various systems have been 
implemented in order to make medicines as affordable as possible. (25)  
Medical aid schemes have contributed to high medicine cost in South Africa through the 
over-utilisation of health care facilities. Therefore, in 1985, the Pharmaceutical Society of 
South Africa (PSSA) implemented the Maximum Medical Aid Price (MMAP) in the private 
sector. (26) This system encourages the use of generic medicines by contracting medical aid 
schemes to pay only a specified maximum price for generically equivalent medicines. 
Another benefit of the MMAP is encouraging rational medicine use by making general 
practitioners more aware of their prescribing practices. (26)   
A study conducted by Deroukakis (2006), found that although generic prescribing is 
practiced in the public sector, the beneficiaries of medical aid schemes have the option 
whether or not to choose a generic medicine, if a branded medicine is prescribed. (27) The 
difference in the cost of the final medicine selected (if higher than the medicine on the 
formulary of the medical scheme) is borne as a co-payment by the patient. According to this 
study, Discovery Health introduced a new policy in January 2004 in their support for generic 
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substitution. Through this policy a 10% levy would be waived on the medication bill of 
beneficiaries who opted for generic medicines. This aimed to increase the use of generic 
medicines in an effort to diminish health care costs. The study indicated that the greatest 
increase in medical aid claims for generic medicines occurred prematurely, in anticipation of 
the implementation of the law. (27) 
 
2.7 Pricing of generic medicines internationally 
Health care costs are rising significantly around the world. (28) There is an increase in chronic 
diseases due to ageing populations with stricter clinical targets for managing these patients. 
The continued launch of new and more expensive medicines as well as rising patient 
expectations have also contributed to high medical costs. (28) In an attempt to reduce the cost 
of generics and promote its use, many countries have implemented cost saving pricing 
policies. A study conducted by Hassali et al (2013), explored the generic medicine policies 
implemented in eight countries (29): 
 In the United States, patients are encouraged to use generic medicines by making 
them pay significantly lower co-payments when selecting generic medicines. (29) In 
2009, the average co-payment for a generic medicine was $7 while branded medicines 
reached up to $75. (30) 
 In the United Kingdom, the Drug Tariff Price of generic medicines is set well below 
the price of branded medicines. (31) In order to further encourage the use of generic 
medicines, manufacturers offer substantial discounts to pharmacies, exceeding 60 – 
80% for some medicines. (32) 
 In Australia, a mandatory 12.5% price reduction policy was implemented in 2005. 
The policy stipulates that the first new generic version of a medicine must be priced at 
least 12,5% below the current lowest priced brand. (29) Generic medicine 
manufacturers also provide significant discounts of up to 50% to pharmacies thereby 
promoting the use of these medicines. (33) 
 In Japan, financial incentives are provided to physicians that prescribe generic 
medicines and to pharmacists if generic medicine usage in their pharmacy is over 30% 
in a 3 month period. (29) In addition, pharmacists are given financial incentives to 
educate consumers about generic medicines. (34) 
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2.8 Cost saving benefits of Generic substitution in South Africa 
In South Africa, like other developing countries with limited health care budgets, generic 
medicines can be a cost-saving policy alternative as generic medicines are considerably less 
expensive than innovator medicines. (35) A study conducted in Durban by Abdool Karim et al 
(1996) explored the potential savings from generic prescribing and generic substitution in 
South Africa. (36) This was done by collecting computer printouts of prescriptions from 
pharmacists as well as the original doctor’s prescription and pricing them for comparison. It 
was found that the cost of the prescription as dispensed was 1,4% below that of the original 
doctors prescription. (36) There is therefore a marginal benefit from the current low 
substitution rate of 13,9% by pharmacists with a maximum potential saving of 9,9% from 
generic prescribing and substitution. The study concluded that although cost savings were 
marginal, generic substitution has the potential to reduce medicine costs. (36) 
Generic substitution in the private sector has the potential to cut medication costs 
significantly. (27) The Medicines and Related Substances Control Amendment Act No. 90 of 
1997 was designed to enable the government to undertake a variety of actions in order to 
ensure a supply of affordable medicines. (27)  
Research into cost savings from generic prescribing and substitution of  three medicine 
classes of antihypertensives, hypolipidaemic agents and antidepressants in South Africa has 
shown that, depending on the medicine involved, savings range from 9,9–59,7% (mean 
41,1%). (37) It has also been reported that further savings of 10% could be gained if generic 
prescribing and substitution are practised to maximum capacity in South Africa. (37) 
According to research carried out by van der Westhuizen et al from 2004, savings of 9,3% 
over a 3-year study period could have been made with generic substitution of antidepressants. 
This translated to a 0,4% saving for the total database. It was however noted that total 
substitution would be unlikely, as in 40–60% of cases prescribers and patients would opt for 
the innovator or brand-name product. (35) 
Reports have indicated that approximately 45% of brand medicines in the South African 
market are currently substituted for less expensive generics, as compared to 54% in the US. 
(35) There is therefore still some room for potential further savings to be made. (35) A study 
was conducted by McIntyre et al (1996) to investigate the extent to which generic prescribing 
by private sector medical doctors as well as generic substitution by private community 
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pharmacists was practiced in South Africa and to determine the potential savings from this. (4) 
It was found that both generic prescribing and generic substitution are able to reduce 
medicine costs. However these practices need to be actively encouraged in order to achieve 
maximum capacity. It was however, noted that the potential savings from generic prescribing 
and substitution are at most 9,9% in the absence of any changes in types of medicines 
prescribed. It was recommended that generic prescribing be encouraged through continuing 
medical education programs for private medical practitioners in South Africa. (4) 
However, successful uptake of the generic substitution policy is dependent on society having 
confidence in the efficacy, safety and quality of generic medicines. The table below (2.1) was 
published by Boyce and Bartlett in a review in the South African Medical Journal (1990). (26) 
From this table it can be seen that significant savings were gained through the use of generic 
medicines from as far back as 1989 when fewer generics were on the market. As generic 
companies manufacture more medicines, it is hoped that competition between manufacturers 
and an increase in demand for generics will further reduce prices and increase savings. 
 
Table: 2.1 Examples of price differences between original and generic 
brands in South Africa, March 1989 (Boyce and Bartlett, 1990) 
 Wholesale Price (R) 
Generic Product Pack size Original Brand Generic Brand % Saving 
Ampicillin 250mg capsules 20 5,94 4,58 22,9 
Methyldopa 250mg tablets 100 36,12 19,72 45,4 
Allopurinol 300mg tablets 30 30,63 15,36 49,9 
Co-trimoxazole tablets 20 13,31 5,20 60,9 
Propranolol 40mg tablets 50 23,67 7,33 69,0 
Diazepam 5mg tablets 100 25,45 3,83 85,0 
Furosemide 40mg tablets 250 177,43 14,70 91,7 
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These results can be compared to more recent studies. One such study was conducted by 
Gray A et al (2009), (38) focussing on the potential cost savings from substituting generics for 
original medicines in 25 chronic diseases. The results revealed that between 19.5% and 97% 
savings can be achieved through generic substitution. The study also found a correlation 
between the cost difference of generic and original medicines and the number of generics 
available for a specific disease state. It was observed that in most cases, as the number of 
generic versions were available, the cost difference between the original and the generic 
medicines increased. (38)This is due to competition within the market. South African 
manufacturing companies should therefore be encouraged to continue producing generic 
medicines in order to increase the number of generic options available, increase competition 
and therefore reduce costs of medication. (38)   
By comparing recent data with older studies, we can observe the progression in the generic 
policy benefits over the past 3 decades and entrench the importance of on-going cost saving 
advantages from generic substitution.  
2.9 Generic substitution in South Africa 
Although generic medicine usage in South Africa is increasing, it is still relatively low 
compared to Western countries.  This slow uptake of generic usage could be attributed to a 
lack of trust in the medication by physicians, pharmacists and consumers due to a belief that 
generics are of an inferior quality. It can be seen in Table (2.2), published by McDonald 
(2004) that generic medicine use in South Africa is significantly lower than other major 
developed countries. (39) 
Table: 2.2 Comparing generic medicine usage in South Africa to other 
major countries (Mc Donald, 2004) 
Country Generic Medication as a % of Market 
South Africa 19 
United Kingdom 70 




Doubts surrounding generic medicines is however still a concern. Possible reasons for this 
could be (40) : 
 Patients wanted to stick to brands they recognise and trust 
 Lack of trust in generic companies 
 Non-transparency of decision making by regulatory authorities leading to distrust 
 Provision of incentives by manufacturers to both prescribers and pharmacists 
influencing which medicines are prescribed and dispensed 
 Anecdotal evidence of generic medicines being of a low quality 
 The huge effort that is required to get prescribers to prescribe generic medicines 
A study conducted by Kyenda et al (2004), reviewed a total of 2352 prescriptions by doctors 
in Umtata. (41) Of these prescriptions, it was noted that 57,7% were medical aid patients and 
41,7% were cash patients. The prescribing trends revealed that 10,4% of prescriptions 
contained generics alone. 83,2% of prescriptions contained only original medicines and 6,4% 
of prescriptions had both generic and original medicines. (41) Generic prescribing is therefore 
low in this area and prescribing doctors should be educated on rational medicine use and 
encouraged to prescribe generic medicines. 
Figure 2 below provides insight into the percentage of generic and original medicines 
available in the South African market over a 5-year period. Through this graph, it is evident 
that generics are progressively increasing in usage with 35% of the market being generics in 
2002 to almost 54% in 2006. Generics now make up a larger proportion of the medicine 
industry than originals. These findings are a positive indication that the country is moving 



















2.10 Generic substitution internationally 
Encouraging greater use of generic medicines is an internationally recognised practice for 
reducing costs of medicines to patients. A study published by Shrank et al (2010), in the 
United States, evaluated the relationship between three state-level policies and generic 
substitution rates after the patent expiration of Zocor®, one of the world’s top-selling 
medications. (42) To address the increasing cost of medicines, states had implemented varying 
generic substitution policies. These policies differed in the extent to which pharmacists or 
patients can influence the choice of medicine. Some states had adopted mandatory generic 
substitution laws that required pharmacists to substitute a generic for a branded medication if 
the prescriber did not otherwise specify. (42) Some states did not require pharmacists to 
substitute generics, providing them with more discretion with regard to medication 
utilization. In addition, other states required the patient to provide consent prior to 
substitution of a generic. It was found that states implementing policies that required a patient 
to consent before generic substitution had a 25% lower rate of generic substitution. (42) The 
study concluded that while it was generally appealing to provide patients with more choice in 
their medical care, a more restrictive approach to generic substitution may lead to cost 
Figure 2: Generic and Original medicine usage in South Africa  
(2002 – 2006) (South African National Database, Jan 2007) 
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savings without compromising quality, providing greater opportunities to invest healthcare 
dollars more cost-effectively. (42) 
The pharmaceutical expenditure in Sweden has increased during the last few decades. (43) A 
mandatory generic substitution policy was introduced on 1 October 2002 with the aim of 
reducing the growth in pharmaceutical expenditure. (43) A study conducted by Andersson et al 
(2007), investigated the implementation of the policy and whether it was associated with 
changes in patients' expenses and reimbursed cost for prescribed pharmaceuticals that were 
included in the Swedish Pharmaceutical Benefits Scheme. (43) The study found that the 
introduction of generic substitution was associated with a shift in trend from an increase into 
a decrease in expenditure for both for patients and society. This suggested that generic 
substitution has contributed to a reduction in the growth of pharmaceutical expenditure. (43) 
In the UK, generic medicine use was raised as a means of reducing the NHS (National Health 
Scheme) medicines bill in the Greenfield Report of 1983. (44) This recommendation was not 
implemented, but activity to encourage generic prescribing did result in a change in doctors' 
prescribing habits towards the greater use of generics. Within a decade, the overall shape of 
the NHS market had changed such that by 1993 generic products accounted for 11% of the 
NHS expenditure on medicines and 41% of the volume. (44)  
As evidence mounts, governments are more convinced that generic substitution of branded 
products plays an important role in limiting the cost of medicines in many countries. 
However, strict regulations are required to ensure that marketed generics are bioequivalent to 
branded products 
 
2.11 Factors impeding generic medicine use 
Physician prescribing behaviour is an important influence in generic medicine use. An 
obstacle to this may be physicians concerns about the safety and efficacy of generic 
medicines as well as a tendency to prescribe by habit. (45) A study conducted in United States 
outpatient practices in 2007 found that the most physicians link medicines to their brand 
name rather than generic name. (46) This results in physicians prescribing by brand name. This 
reflects the tendency of physicians to prescribe by habit rather than an intentional use of 
brand name medicine. In this scenario, allowing pharmacists to substitute generic medicines 
can be a key factor in maintaining high generic usage. (46) 
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Differences between branded and generic medicines exist that may influence the physician to 
prescribe the branded medicine. (45) Generic medicines may differ from the branded medicine 
in terms of inactive ingredients without interfering with therapeutic equivalence comparisons. 
(44) Patients may present with sensitivities or allergies to inactive ingredients that may require 
the use of a branded medicine. Physicians may erroneously believe that there are safety or 
efficacy differences between the branded and the generic medicine. (45) 
A study conducted with 1253 pharmacists by Kobayashi et al (2011) in Japan found that most 
pharmacists were in favour of dispensing generic medicines, but that they would need to 
determine if generic medicines were appropriate for the patient. (47) They provided three 
reasons for preventing them from undertaking generic substitution:  
 “The generic medicine may not be in stock or no generic equivalent is available yet in 
the market, (47) 
 Only a very small cost savings resulting in patients' objections, physicians' objections 
and (47) 
 Presence of scepticism in the quality of generic medicines and inadequate medicine 
information from generic manufacturers”. (47) 
 
2.12 Studies relating to perceptions and knowledge of Generic medicines in South 
Africa 
Although physicians and pharmacists select appropriate medicines on the patients’ behalf, it 
is still the final choice of the patient whether or not to use the generic medicine. (45) Patients 
can communicate to their physicians or pharmacists their preference for branded medicines. 
Patients can discuss with their physician or pharmacist what their preferences are. Patients’ 
preference for branded medicines may depend on a number of factors, including medicines 
the patient is currently using or has used in the past, knowledge about the specific generic or 
branded medicines, general knowledge about generics and branded medicines, and financial 
incentives to use generic medicines. (45) 
A South African study relating to patients/consumers perceptions of generic medication was 
conducted by Patel et al, in the cities of Durban, Cape Town and Johannesburg between 
December 2005 and January 2006. (48) This study explored South African consumer 
perceptions of medicine quality and whether these perceptions influenced how people 
procured and used their medicines. (48) The outcome of the study revealed that generic 
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medicines were considered to be poor quality by consumers and treated with suspicion. 
Consumers indicated that their influence was limited in terms of selection of prescription 
medicines and that they would accept generic substitution if it was supported by the doctor 
rather than the pharmacist. The findings emphasized the importance of strategic initiatives 
targeted at consumers and prescribers regarding the quality of generic and essential 
medicines. (48) 
There are, however, only a few studies concerning health providers’ attitudes and 
perceptions. Pharmacists often being the first point of contact for consumers can be a very 
important source of information to introduce generic medicines, (49) hence, quality use of 
generic medicines can be promoted with a better understanding of pharmacists’ views, 
knowledge and perceptions. (50) With the increasing emphasis on pharmaceutical care in the 
practice of pharmacy, the role of pharmacists has been undergoing vigorous expansion. A key 
factor in the success of pharmaceutical care is the quality of patient-pharmacist relationships. 
Patients trust pharmacists to manage their health and well-being and thus pharmacists are 
required to accept responsibility to care for the well-being of the patients. (51) This trust is 
based on the expectation that pharmacists will do what is best for patients. (51)  
 
2.13 International studies relating to perceptions and knowledge of Generic medicines  
A cross-sectional descriptive study by Chong et al (2011) involving the entire population of 
practicing community pharmacists was undertaken in the State of Penang, Malaysia. (52) A 
self-completed anonymous mail questionnaire was used to explore the pharmacists’ views on 
generic medication and concluded that “the pharmacists' have lack of information and/or 
trust in the generic manufacturing and/or approval system in Malaysia and that the issue 
should be addressed by pharmacy educators and relevant government agencies”. (52) 
A similar cross-sectional descriptive study involving community pharmacists in Amman-
Jordan in 2013 was undertaken, using a self-completed anonymous questionnaire. (53) This 
study, however, found that most of Jordanian pharmacists are positive about generic 
medicines in general with more than 80% of the pharmacists supporting generic substitution 
and being in favour of implementing a compulsory generic substitution policy. (53) 
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In both studies, implementing generic medicines prescribing and substitution policies in order 
to improve the medicines affordability was a recommendation as the majority of the 
community pharmacists in Penang and Amman. Generic substitution policy is being 
implemented by these pharmacists by actively promoting generics in their current practice. 
(52) 
Another interesting study was conducted in New Zealand by Babar et al (2010) that also 
explored the views and opinions of pharmacists relating to generic medicines. (50) The results 
of this study revealed that only about one-third of pharmacists had the correct knowledge of 
the definition of generic medicines, which reflects the variability in pharmacists’ knowledge 
and perceptions of generic medicines. While most of the pharmacists acknowledged the 
economic benefits of generics to the health care system, they were concerned about quality, 
safety, and effectiveness issues. (50) 
A study by Gossell-Williams (2005) was conducted in Jamaica, exploring the acceptance and 
perceptions of generic substitutions by physicians yielded interesting results. (54) Less than 
50% of responding physicians were prescribing generic medicines willingly as they had 
doubts about whether a generic was therapeutically equivalent or bioequivalent to the original 
medicine. The study concluded that greater emphasis should be targeted towards improving 
physician confidence in the therapeutic equivalence of generics. (54) 
In both these studies, health care professionals showed very low understanding of generic 
medicines, and their lack of awareness denied patients of the benefits of cost-effective 
appropriate treatment. The studies indicated that there is a need for education on generic 
medicine supported by adequate support facilities for appropriate, affordable, safe, and 
effective use of generic medicines.  
A study by Fischer et al (2003), undertaken in the United States, assessed the potential 
savings from increased use of generic medicines in the elderly as it was found that little was 
known about the extent to which such savings are achieved in medicine benefit programs 
serving them. (55) The study compared the expenditures for brand name prescriptions and 
determined what would have been paid for generic versions of the same medicines in a 
Medical aid program and in a non- Medicaid medicine insurance program for the elderly. The 
findings suggested a large amount of unrealized savings nationally on prescription medicines 
in health insurance programs serving the elderly. (55) This is an important finding as the 
population of older patients in the United States is increasing and thus generic substitution 
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can avoid excess expence without compromising clinical outcomes. The study also concluded 
that US physicians have a poor understanding of the FDA regulations covering generic 
products and vary widely in their beliefs and actions regarding generic substitution. (55) The 
study suggested that marketing information might convince physicians or patients that brand-
name medicines offer superior efficacy or demands higher manufacturing standards, even if 
no data supports this assertion. (55) 
 
2.14 Factors influencing consumer purchasing of generic vs. originator medicines 
The cost of medicines in developing countries, may add up to 30-40% of health expenditure. 
In most cases, these payments are made by patients purchasing medication for self-
medication and rarely on prescription. (56) By determining how and why consumers make 
these choices and understanding what factors influence their behaviour, steps can be taken in 
order to ensure that these precious resources are spent as safely and productively as possible. 
(56) 
A study conducted by Igbinovia (2007) attempted to assess the impact that demographic 
factors such as race, income, educational level and age, have on the use of generic vs. 
branded medicine. (57) The study yielded interesting results as it was found that the white 
population are less likely to use generic medicines when compared to blacks possibly due to 
the differences in income distribution between the 2 races. (57) Age was also a determining 
factor as results revealed that older people were more likely to buy generic medicines instead 
of branded medicines. As far as educational level was concerned, findings suggested that the 
higher the educational level, the more likely the consumer was to choose generics. This was 
most evident with female participants. The impact of factors such as the availability of 
medical aid, cost, and safety of medicines were also assessed and it was found that people 
with medical aid had a greater tendency to choose branded medicines over generic medicines 
when compared to cash patients, as they did not have the burden of paying for their 
medication directly.(57) 
In America, more than $20 billion/year was spent by consumers on over the counter (OTC) 
medication. (58) A survey based study conducted in The United States in 2012 sought to 
determine the factors influencing US consumers’ choice to purchase generic medicines as 
opposed to brand name OTC medicines. (58) The study found that the majority of participants 
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indicated that OTC generic medicines are equally as effective and safe as brand name 
medication. Although economic factors play a vital role in influencing consumer’s decision 
to choose generic medications, various factors, such as advertising, duration of OTC 
effectiveness, severity of illness, preferable dosage form of medication, safety, relief of 
multiple symptoms, and loyalty to a preferred company, will influence consumers decisions 
to pay more for a brand name medicine. (58) 
In both these studies it was important to explore the factors influencing consumers’ choice of 
generic medicines versus brand name medicines, in order to increase awareness and use of 
generic medication. Through this understanding, cost saving strategies can be implemented 
for consumers in order to help curb rising medicine costs. In both cases, better education lead 
to better use of generics. This suggests that pharmacists are able to influence patient choices 
by better educating patients on generic medicines. 
 
2.15 Rationale for study 
Pharmacists play an integral role in the decision-making process for medicine use.  
Pharmacists make decisions as to which generic medicines to stock and/or dispense as well as 
promote generic medicine use in their practice by educating patients on the use of these 
agents. However, there are various factors that influence their decision-making process, such 
as differences in pharmacists ’attitudes towards the use of generic medications in their 
practice, the therapeutic index of the medication as there would be a tendency to avoid 
medicines with a narrow therapeutic index (NTI), as well as the quality of generic products 
across suppliers. 
This study in South Africa was aimed at investigating the knowledge, perception, and attitude 
of community pharmacists towards generic medicines in order to encourage the use of 
generic medication. Through this, wider support can be gained from health professionals’ for 
the quality and rational use of generic medicines. There is little known about the perception 
of pharmacists to generic substitution in this country, as a factor that may hinder or assist this 




CHAPTER 3: METHODOLOGY 
 
3.1 Study location 
The Western Cape Province 
Of the nine provinces in South Africa, the Western Cape (WC) is the fourth largest in terms 
of both area and population. It encompasses an area of 129,449 square kilometres and 5,8 
million inhabitants. (59) The vast majority of the population (89,6%) live in urban areas, which 
comprises of metropolitain areas and secondary cities or small towns. (60) This figure is 
relatively high compared to the national average 63 – 37 urban – rural split according to a 
paper published by Punt et al (2005) that evaluated the profile of the Western Cape Province. 
(60) About two-thirds of the Western Cape inhabitants live in the Metropolitan area of Cape 
Town, which is also the provincial capital. (58) Table 3.1 below provides an insight into the 
vast number of public health facilities available that caters for the health needs of each of the 
5 districts in the province. (61) 
 
Considering that the majority of South Africa's population had little or no access to quality 
medical attention until the 1990s, the healthcare system in Cape Town has made great strides 
to improve its standards and serve the communities that need it most. (61) According to 
statistics released by the South African Pharmacy Council (SAPC), (62) the Western Cape has 
the second largest number of registered pharmacists (15,18%) (See Table 3.2). The Western 
Cape Province was chosen as the area of study, as the researcher resides in this area. In 
addition it has a large number of pharmacists that would provide a population and a sample 
large enough to extract as accurate results as possible. This province was also selected as it 
boasts world reknowned hospitals such as Groote Schuur and leading medical schools in 
Cape Town and Stellenbosch. The city of Cape Town has become a hub for research and 
innovation, with the Third Global Symposium on Health Systems research being hosted 
recently in 2014. Through this, one would anticipate that pharmacists would be implementing 








Table 3.1: List of facilities located within the Western Cape (Expat arrivals, 2014) 











Total Primary Healthcare 
Facilities 
District Hospitals Regional Hospitals 
2013 2012 2011 2013 2012 2011 2013 2012 2011 
City of Cape 
Town 
9 37 82 4 17 149 149 159 9 9 9 2 5 5 
West Coast 
District 




0 6 42 28 6 82 82 84 4 4 4 2 2 2 
Overberg 
District 
0 1 22 14 7 44 44 47 4 4 4 0 0 0 
Eden District 0 5 33 21 12 71 71 76 6 6 6 1 1 1 
Central Karoo 
District 
0 1 8 10 3 22 22 20 4 4 4 0 0 0 





3.2 Study design 
A cross sectional study was conducted by means of an electronic questionnaire, using Survey 
Monkey from 7 September 2014 to 7 October 2014. Surveys have been widely used as a 
research technique to assess pharmacists’ views, knowledge and perceptions. The study 
followed a quantitative method design and involved the analysis of numerical data. 
 
3.3 Questionnaire development 
A literature review on similar studies held around the world was conducted using electronic 
databases. This insight allowed for the development of a questionnaire that thoroughly 
explored the relationship between pharmacists and the use of generic medication. Once the 
questionnaire was constructed, using the online program SurveyMonkey, supervisors from 
the Discipline of Pharmaceutical Sciences gave feedback on the appropriateness of questions, 
layout, sequence and themes. (Thus face validity was conducted) The first part of the 
questionnaire included demographic data such as age, gender, years of experience and 
pharmaceutical sector of work. The second part assessed knowledge of generic medication, 
 Table: 3.2 
Number of Pharmacists registered with SAPC in 2014 in 
each South African Province (SAPC, 2014) 
Province Total Registered Total Registered (%) 
Eastern Cape 939 7,03 
Free State 429 3,21 
Gauteng 4463 33,40 
Kwa Zulu Natal 1717 12,85 
Limpopo 436 3,26 
Mpumalanga 530 3,97 
Northern Cape 171 1,28 
North West 601 4,50 
Western Cape 2028 15,18 
Unknown  2050 - 
South Africa 13364 - 
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safety, quality and effectiveness using Likert Scale measures. Participants chose a number 
from 1 – 5 each corresponding to options from strongly disagree to strongly agree. The third 
part assessed perceptions relating to generic medicines manufacturing as well as pricing. The 
last part evaluated the pharmacists’ behaviour when dealing with generic medicines. The 
majority of questions were close ended, however, pharmacists were provided the opportunity 
to give comments (refer to Appendix A for the Questionnaire).  
 
3.4 Sampling  
RAOSOFT information 
A sample size was calculated from the population in order to gain a variety of data and 
establish accuracy of results. A list of the contact information of 2003 registered pharmacists 
residing in the Western Cape was obtained from the South African Pharmacy Council 
(SAPC). Of this, 230 had no email addresses and 43 emails bounced, resulting in a sample 
population of 1730. Sample size was calculated with a 5% margin of error, a 95% confidence 
interval and a 50% response distribution using ‘Raosoft’ (63), a sample size calculator. A 
random sample of 315 was therefore required. The total population of 1730 pharmacists was 
therefore selected after taking into consideration the possibility of non-respondents in order 
to arrive at the required sample size.  
 
3.5 Data collection  
Surveys were emailed for a month starting from the 7th of September; thereafter reminder 
emails were sent to pharmacists every few days until the 7th of October until a total of 321 
pharmacists had responded.  
 
3.6 Statistical Analysis 
An exploratory data analysis plan was used. The objectives were to suggest possible 
hypotheses relating to the causes of observed phenomena, to assess the assumptions on which 
statistical inference were based, to support the selection of appropriate statistical tools and 
techniques as well as to provide a basis for further data collection. P and Chi-Squared values 
were calculated for graphs using ‘Social Science Statistics, 2014’ .In order to reject the null 
hypothesis and prove a significant finding, the chosen significance level for the P-value was 
set at 5% (P < 0,05). Descriptive statistics were also used in order to provide a quantitative 
description on the demographics of all respondents. Further analysis was also conducted to 
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identify if differences existed between variables such as age, gender and pharmaceutical 
practice sector.   
 
3.7 Ethical Considerations 
The ethical approval was obtained from the Biomedical Research Ethics Committee on the 
19th of August 2014 (Brec REF: BE317/14) (see Appendix B). Participants were required to 
sign (or tick) an informed consent agreement before answering the questionnaire. The 
consent form indicated that participation was voluntary and that respondents could withdraw 




CHAPTER 4: RESULTS 
 
Out of the 1730 pharmacists that were emailed the questionnaire, 321 of them had responded, 
which equated to a response rate of 18.6%. Descriptive data will be presented first and 
analytical results thereafter. 
 
4.1. Descriptive Results of the Study 
4.1.1Demographics of the respondents 
It can be noted in Table 4.1 that more than 60% of respondents were female.  
 
 









Demographic Data – Age of Participant 
Age Response (n = 312) Response (%) 
20 – 30 48 15,4 
31 – 40 88 28,2 
41 – 50 63 20,2 
>50 113 36,2 
Table: 4.1 
Demographic Data – Gender of participant 
Gender Response (n= 312) Response (%) 
Male 124 39,7 








The majority of respondents (73%) possessed a qualification in bachelor of pharmacy, with 
more than 15% of pharmacists also holding a postgraduate qualification (Table 4.3). 
Interestingly, the majority of respondents came from pharmacists that were working in the 
pharmaceutical field for the longest time, with almost half (46%) of respondents coming from 
those with over 20 years of pharmaceutical experience (Table 4.4).  
 
 
Most pharmacists (40,4%) worked within community pharmacies, with the second most 
common sector being public institutions (22,0%). 55 pharmacists responded that they worked 




Basic Pharmaceutical Qualification of Participant 
Qualification Response (n= 312) Response (%) 
Dip. Pharmacy 34 10,9 
Bachelor of Pharmacy 230 73,7 
Postgraduate qualification 48 15,4 
Table: 4.4 
Years of Experience of Participant 
Years Response (n= 310) Response (%) 
1 – 5 43 13,9 
6 – 10 49 15,8 
11 – 15 49 15,8 
16 – 20 26 8,4 
>20 143 46,1 
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Some of the most common responses are tabulated below 
 
 
4.1.3 Pharmacists’ knowledge of generic medicines 
More than 70% of pharmacists agreed that generic medicines are therapeutically equivalent 
and interchangeable with their original counterparts (see Table 4.7). Majority (82%) of 
pharmacists disagreed with the statement that generics are less safe than original medicines. 
Most respondents (80%) reported no difference in side effects between generic and original 
brands. Although 54% of respondents felt there was no difference in quality between original 
and generic medication, more than 20% of pharmacists believed that original medicines 
underwent stricter safety regulations than generic medicines. 
Table: 4.5 
Pharmaceutical sector Currently working in 
Sector Response (n= 332) Response (%) 
Community Pharmacy 112 40,4 
Institutional (private) 41 14,8 
Institutional (public) 61 22,0 
Academic institution 20 7,2 
Wholesale Pharmacy 9 3,2 
Manufacturing pharmacy 29 10,5 
Consultant Pharmacy 5 1,8 
Other 55 - 
Table: 4.6 
Other common Pharmaceutical employment sectors 
Sector Response (n= 37) 
Managed health care 13 
Retired 10 
Research 6 





Pharmacists’ knowledge of generic medicines 
 
Answer Options Strongly 
Disagree 








Generic medicines are a copy of original medicines 3,8% 10,3% 12,8% 52,8% 20,3% 3,8 290 
Generic medicines are interchangeable with original 
medicines 
0,3% 8,6% 13,1% 56,6% 21,4% 3,9 290 
Generic medicines are therapeutically equivalent to original 
medicines 
1,0% 7,9% 16,3% 50,5% 24,2% 3,9 289 
Generic medicines must be in the same dosage form (such 
as tablet, capsule) as original medicines 
3,1% 16,7% 8,3% 42,0% 29,9% 3,8 288 
Generic medicines are less safe than original medicines 32,9% 49,5% 13,1% 3,5% 1,0% 1,9 289 
Only those generic medicines which are made by some 
local reputable manufacturers are safe 
20,8% 35,1% 17,0% 21,1% 5,9% 2,6 288 
Generic medicines are manufactured after the patent expiry 
of originator/innovator 
2,0% 2,8% 4,1% 55,9% 35,1% 4,2 290 
Original medicines are of a better quality than generic 
medicines 
18,8% 35,3% 28,8% 13,4% 3,8% 2,5 292 
Original medicines are required to meet higher safety 
standards than generic medicine 
25,0% 44,4% 10,8% 15,3% 4,5% 2,3 288 
Original medicines produce fewer side effects than generic 
medicines 
29,5% 50,0% 14,6% 5,6% 0,35% 2,0 288 
Low-priced medicines are as effective as high-priced 
medicines 
1,0% 6,2% 20,7% 46,2% 25,9% 3,9 290 
answered question 293 
skipped question 26 
 43 
4.1.4 Pharmacists’ perceptions of generic medicines 
About 70% of pharmacists believe that locally manufactured medicines are more affordable 
and have the same level of effectiveness as original medicines (see Table 4.8). However, a 
significant disparity was observed with the statement that few local companies are reputable 
generic medicine manufacturers, with 46% disagreeing with this statement and 38% agreeing 
with it. More than half of the respondents believed that pharmacists should be educated more 




Pharmacists’ perceptions of generic medicines 
 
Answer Options Strongly 
Disagree 








I believe that locally manufactured medicines are 
more affordable than original medicines 
1,4% 9,6% 19,5% 53,9% 15,6% 3,7 282 
I believe that locally manufactured medicines are of 
the same effectiveness as original medicines 
0,4% 2,1% 24,8% 56,4% 16,3% 3,9 282 
I view generic medicines as being of a poorer 
quality than original medicines 
23,5% 49,5% 30,0% 5,0% 1,1% 2,1 281 
I think generic medicines produce more side effects 
than original medicines 
24,6% 54,6% 15,1% 4,9% 0,7% 2,0 284 
I believe low-cost medicines are as safe as high-
cost medicines 
0,4% 3,9% 16,3% 59,9% 19,5% 3,9 282 
I believe that multinational products are of a better 
quality than locally produced products 
19,7% 45,8% 22,2% 12,3% 0% 2,3 284 
I believe that the local companies in South Africa 
are not following Good Manufacturing Practice 
(GMP) guidelines as well as multinationals 
27,9% 48,4% 19,4% 3,9% 0,4% 2,0 283 
I view few local companies as reputable generic 
medicine manufacturers 
11,7% 33,9% 15,9% 30,0% 8,5% 2,9 283 
I believe that pharmacists should be educated more 
about prices of medicines 
4,3% 17,4% 20,6% 40,8% 17,0% 3,5 282 
I believe that generic medicines are only meant for 
the poor 
51,8% 43,3% 2,1% 2,5% 0,4% 1,6 282 
I think that confidence should be built in the patient 
about the low-cost brand 
1,1% 3,5% 11,0% 53,9% 30,5% 4,1 282 
Wider use of generic medicines will mean that less 
money will be used for research and development 
of new pharmaceuticals. 
14,9% 37,9% 22,7% 18,1% 6,4% 2,6 282 
answered question 284 
skipped question 35 
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4.1.5 Factors associated with support for generic substitution 
The most popular reason for pharmacists recommending a generic alternative to patients was 
‘cost to customer’, with 91% of respondents choosing these options. Other significant reasons 
were ‘medical scheme requirement’ and ‘proven bioequivalence’ with 80% and 66% of 
responses respectively.  
 
Table: 4.9 
Reasons for recommending a generic alternative 




Cost to customer 91,6% 261 
Having no other choice 22,5% 64 
Customer preference 56,1% 160 
Availability of stock 58,9% 168 
Customer appearance 2,8% 8 
Cost effectiveness 73,0% 208 
Proven bioequivalence 67,0% 191 
Medical scheme requirement 80,0% 228 
Do not recommend generics 0,7% 2 
Other (please specify) 10 
answered question 285 
skipped question 34 
 
4.1.6 Factors affecting generic substitution 
Most pharmacists (83%) responded that they would dispense the original medicine if the 
customer refused to accept a generic. Only 14% of pharmacists would take the time to 
persuade the patient to use a generic instead. A significant 60% of respondents stated that 
doubts regarding bioequivalence of generics were one of the problems when switching to a 
generic alternative. Patients’ lack of confidence in generic medications relating to efficacy 
and safety was also a problem encountered. Another major factor influencing generic 
substitution is stock availability of the generic medicines.  
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Table 4.10: Factors Affecting Generic Substitution 
Answer Options Response Percent Response Count 
Approach when a patient refuses a generic 
I dispense the Original 82,4% 225 
I persuade the patient 14,3% 39 
I direct him/her to the prescriber 2,6% 7 
I direct him/her to another pharmacy 0,7% 2 
Possible problems that you have noticed when switching to a generic medicine 
No idea 17,5% 40 
Concern about losing the patient 8,3% 19 
Too much effort to persuade the patient 23,6% 54 
Doubts about the bioequivalence 60,3% 138 
Other 64 
Other possible problems noticed when switching to a generic medicine 
Patient distrust in generic medicines 28,1% 18 
Side effects and ineffectiveness experienced with generic medicines 23,4% 15 
No problems experienced 18,8% 12 
Patient non-compliance 3,1% 2 
Public sector only uses generics 3,1% 2 
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In terms of other problems that were encountered, there were 2 common responses. About 
28% of pharmacists cited a lack of patient confidence in generic medicines as being a 
problem. The reasons that they gave were that patients want exactly what the doctor 
prescribes or they may have doubts about the efficacy and safety of generics.  
The 2nd common response was that side effects and ineffectiveness was observed when 
patients were switched to a generic medicine. Twenty three percent of pharmacists believed 
that the quality of generic medicines was not equal to that of originals and they do not believe 
that generic medicines are bioequivalent to their original counterparts. 
 
4.1.7 Information sources for generics  
As can be seen from Table 4.11, almost 80% of pharmacists find out about the availability of 
generic alternatives to original medicines through medicine manufacturers and more than 
50% used medical journals and international literature as a source of information. The list of 
generic medicines that can be obtained on computer dispensing software was also a common 
source of information for pharmacists. The open ended question asking for any further 
comments relating to generic medicines received 91 comments. Pharmacists’ opinions 
regarding generic medicines were generally positive and most supported their use as long as 
it was manufactured from a reputable company. A few respondents expressed concerns about 
differences in quality of efficacy of generic medicines amongst different manufacturing 




Information source to find out about the availability of a generic 
alternative to an original medicine 




Medication manufacturer representatives 79,3% 219 
Medication wholesaler 20,7% 57 
Medical journals 51,8% 143 
Medicine company written information 40,9% 113 
From pharmacist/ colleagues/peers 49,3% 136 
From patients 10,9% 30 
From doctors 20,3% 56 
Informational literature ( newsletters, articles) 56,2% 155 
From internet/websites/e-mails 34,4% 95 
From meetings/conferences 30,8% 85 
Other (please specify) 44 
answered question 276 
skipped question 43 
 
4.1.8 Other comments regarding generic medicines 
The open ended question at the end of the survey allowing pharmacists to submit any views 
or recommendations they have regarding generic medication yielded 91 responses. Almost 
10% of responses had positive feedback relating to the cost saving advantages of generic 
medication. About 8,7% of responses discussed generic manufacturers. They felt that not all 
generic manufacturers were reliable and they would only dispense medication from 
companies they trusted. More than 11% of respondants thought that generic medication was 
not bioequivalent to original medicines and were doubtful about substituting certain original 




“Generic medicines are of fundamental importance to our health system and they should be 
supported in every way. They are critical for increasing access to cost-effective care 
(amongst all populations, not just the poor) and more needs to be done to change the 
wrongful perception of consumers and providers (doctors and pharmacists) that generics are 
inferior.” 
“As a pharmacist I would like to have insight in the practical side of the use of generics.  
Sometimes a doctor will say that some generics are less efective that others.  How can I take 
part in this discussion if I have no proof that there is in fact not a difference.” 
“Quality not always good. Availability sometimes a problem”. 
“I have no problem recommending generic equivalents”. 
“Medical professionals require more training/guidance about generic medicines.” 
“The MCC ensures bioequivalence of all available generics” 
“I will recommend a generic product if I am satisfied the manufacturer is reputable” 
“Would not use generic medicines for drugs with narrow therapeutic window” 
“I believe that generics are cost-effective alternatives to originator drugs and pharmacists 
should promote them more actively”. 
“In my experience I have found patients claiming to have undesirable responses (side-effects, 
adverse effects, allergic reactions) to generics and not the original drug. I suspect it is the 
different excipients that could have been used to make it more affordable or just the patients’ 
mental state because they are aware that it is not the original.” 
 
4.2. Analytical Results of the study 
4.2.1Gender comparisons of pharmacist’s knowledge of generic medicines 
Tabulated below (Table 4.12), are the responses given by pharmacists regarding their 
knowledge of generic medicines and a comparison between male and female responses. A 
significant difference between responses is noted when the calculated P value is < 0,05. In 
this table, however, there are no significant findings. This implies that male and female 
pharmacists had similar responses regarding their knowledge of generic medicines 
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4.2.2Pharmaceutical sector comparisons of pharmacist’s knowledge of generic 
medicines 
Table 4.13 has one significant recording with a P value of 0,005 relating to safety of generic 
medicines. The statement was that ‘Original medicines are required to meet higher safety 
standards than generic medicine’. The biggest difference is this category was by consultant 
pharmacists. Pharmacists working in the other sectors all had the fewest number of ‘strongly 
agree with the statement’ responses. However, almost half of consultant pharmacists (40%) 
strongly agreed that original medicines are required to meet higher safety standards than 
generic medicine.  This misconception can lead to a lack of trust and promotion of generic 
medicines.
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Table: 4.12: Gender Comparison of Pharmacists knowledge of generic medicines 
STATEMENT LIKERT SCALE  
 STRONGLY 
DISAGREE 






Generic medicines are a copy of original medicines 3,05 0,55 
Male 3,39 6,78 12,71 54,24 22,88   
Female 4,00 12,57 13,14 51,43 18,86   
Generic medicines are interchangeable with original medicines 1,21 0,88 
Male 0,00 7,69 11,97 57,26 23,08   
Female 0,57 9,09 13,64 56,25 20,45   
Generic medicines are therapeutically equivalent to original medicines 4,89 0,3 
Male 0,00 5,98 18,80 53,85 22,22   
Female 1,7 9,66 14,20 47,73 25,57   
Generic medicines must be in the same dosage form (such as tablet, capsule) as original medicines 3,31 0,51 
Male 3,42 15,38 5,13 43,59 32,48   
Female 2,84 17,61 10,23 40,34 27,27   
Generic medicines are less safe than original medicines 2,65 0,62 
Male 35,04 47,01 11,11 5,13 0,85   
Female 31,82 50,57 14,20 2,27 1,14   
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Only those generic medicines which are made by some local reputable manufacturers are safe 3,70 0,45 
Male 22,22 34,19 11,97 23,08 6,84   
Female 19,89 35,80 19,89 19,32 5,11   
Generic medicines are manufactured after the patent expiry of originator/innovator 2,60 0,63 
Male 1,71 4,27 3,42 58,97 33,33   
Female 2,27 1,70 4,55 53,41 36,93   
Original medicines are of a better quality than generic medicines 3,90 0,42 
Male 17,95 41,88 23,93 13,68 4,27   
Female 19,89 31,25 31,82 13,07 3,98   
Original medicines are required to meet higher safety standards than generic medicine 6,77 0,15 
Male 29,06 47,01 8,55 10,26 5,98   
Female 22,16 42,05 11,93 18,75 3,41   
Original medicines produce fewer side effects than generic medicines 4,96 0,29 
Male 33,33 48,72 10,26 5,98 0,85   
Female 26,70 50,57 17,05 5,11 0,00   
        
Low-priced medicines are as effective as high-priced medicines 2,01 0,73 
Male 0,85 8,55 19,66 45,30 25,64   





Pharmaceutical sector comparison of Pharmacists knowledge of generic medicines 
STATEMENT LIKERT SCALE  
 STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI-SQUARE P VALUE 
Generic medicines are a copy of original medicines 19,05 0,27 
Community Pharmacy 2,73 8,18 11,82 60,00 17,27   
Institutional (private and public) 4,42 8,83 12,41 50,42 23,92   
Academic Institution 0,00 27,78 11,11 44,44 16,67   
Manufacturing and Wholesale Pharmacy 1,79 10,72 21,43 47,32 18,75   
Consultant Pharmacy 20,00 0,00 0,00 60,00 20,00   
Generic medicines are interchangeable with original medicines 16,24 0,44 
Community Pharmacy 0,91 8,18 16,36 60,91 13,64   
Institutional (private and public) 0,00 11,85 6,58 57,46 24,12   
Academic Institution 0,00 5,56 16,67 55,56 22,22   
Manufacturing and Wholesale Pharmacy 0,00 3,71 9,26 59,72 27,32   
Consultant Pharmacy 0,00 0,00 0,00 40,00 60,00   
Generic medicines are therapeutically equivalent to original medicines 18,30 0,31 
Community Pharmacy 0.91 9,09 23,64 49,09 17,27   
Institutional (private and public) 0,88 8,92 11,14 51,05 28,03   
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Academic Institution 0,00 0,00 5,88 70,59 23,53   
Manufacturing and Wholesale Pharmacy 1,79 11,61 21,43 40,18 25,00   
Consultant Pharmacy 0,00 0,00 0,00 40,00 60,00   
Generic medicines must be in the same dosage form (such as tablet, capsule) as original medicines 15,79 0,47 
Community Pharmacy 0,91 15,45 10,00 40,91 32,73   
Institutional (private and public) 5,26 16,23 9,65 41,67 27,20   
Academic Institution 0,00 27,78 5,56 44,44 22,22   
Manufacturing and Wholesale Pharmacy 12,18 24,36 1,93 43,59 17,95   
Consultant Pharmacy 0,00 20,00 0,00 20,00 60,00   
Generic medicines are less safe than original medicines 16,29 0,43 
Community Pharmacy 29,09 46,36 19,09 3,64 1,82   
Institutional (private and public) 36,75 50,42 7,10 4,84 0,90   
Academic Institution 38,89 50,00 11,11 0,00 0,00   
Manufacturing and Wholesale Pharmacy 35,42 55,33 9,26 0,00 0,00   
Consultant Pharmacy 60,00 20,00 0,00 20,00 0,00   
Only those generic medicines which are made by some local reputable manufacturers are safe 13,51 0,64 
Community Pharmacy 15,60 37,61 18,35 20,18 8,26   
Institutional (private and public) 24,39 32,71 21,29 16,36 5,31   
Academic Institution 22,22 27,78 11,11 27,78 11,11   
Manufacturing and Wholesale Pharmacy 26,79 41,07 5,36 25,00 1,79   
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Consultant Pharmacy 25,00 25,00 0,00 50,00 0,00   
Generic medicines are manufactured after the patent expiry of originator/innovator 15,32 0,50 
Community Pharmacy 0,92 4,59 3,67 56,88 33,94   
Institutional (private and public) 2,63 2,19 4,83 54,39 35,97   
Academic Institution 11,11 0,00 11,11 50,00 27,78   
Manufacturing and Wholesale Pharmacy 0,00 0,00 6,25 64,01 29,74   
Consultant Pharmacy 0,00 0,00 0,00 50,00 50,00   
Original medicines are of a better quality than generic medicines 21,86 0,15 
Community Pharmacy 15,45 28,18 32,73 16,36 7,27   
Institutional (private and public) 21,05 40,36 24,56 11,85 2,19   
Academic Institution 16,67 50,00 27,78 0,00 5,56   
Manufacturing and Wholesale Pharmacy 12,07 48,49 29,74 9,70 0,00   
Consultant Pharmacy 60,00 0,00 20,00 20,00 0,00   
Original medicines are required to meet higher safety standards than generic medicine 34,44 0,005 
Community Pharmacy 21,30 41,67 13,89 17,59 5,56   
Institutional (private and public) 30,13 37,13 9,35 20,31 3,10   
Academic Institution 27,78 55,56 11,11 5,56 0   
Manufacturing and Wholesale Pharmacy 26,79 63,40 0,00 8,04 1,79   
Consultant Pharmacy 0,00 40,00 20,00 0,00 40,00   
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Original medicines produce fewer side effects than generic medicines 20,20 0,21 
Community Pharmacy 22,22 51,85 17,59 7,41 0,93   
Institutional (private and public) 30,70 45,62 16,23 7,46 0,00   
Academic Institution 50,00 44,44 5,56 0,00 0,00   
Manufacturing and Wholesale Pharmacy 26,79 66,07 7,15 0,00 0,00   
Consultant Pharmacy 60,00 40,00 0,00 0,00 0,00   
Low-priced medicines are as effective as high-priced medicines 9,20 0,90 
Community Pharmacy 0,91 6,36 21,82 48,18 22,73   
Institutional (private and public) 0,88 7,90 16,67 46,06 28,51   
Academic Institution 5,56 5,56 11,11 55,56 22,22   
Manufacturing and Wholesale Pharmacy 0,00 3,57 23,22 50,90 22,32   
Consultant Pharmacy 0,00 0,00 50,00 25,00 25,00   
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4.2.3 Age category comparison of Pharmacists knowledge of generic medicines  
 
Three significant results were found in this comparison (Table 4.14). The first statement was ‘Generic 
medicines are a copy of original medicines’. The biggest disparity was found in the 20 – 30 age group. 
Although the majority of pharmacists in this age category agreed with the statement, almost a quarter 
(24,45%) disagreed, believing that generics are not identical to their original counterparts. Respondents in 
the other age categories had a much smaller percentage disagreeing with the statement. 
 
The second significant finding was related to generic medicine manufacturers. More than a third (37,50%) 
of respondents in the >50 age category agreed with the statement that ‘Only those generic medicines which 
are made by some local reputable manufacturers are safe’.  Agreement in the other age categories was 
much lower, ranging from 13,33% in the 20 – 30 age group to 29,27% in the 31 – 40 age group. 
 
The third significant finding was related to efficacy of generic medicines. Only 62,85% of respondents in 
the >50 age category agreed with the statement that ‘Low-priced medicines are as effective as high-priced 
medicines’ compared to a range of 73 – 82% in the younger age groups. 
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Table 4.14:  Age category comparison of Pharmacists knowledge of generic medicines 
STATEMENT LIKERT SCALE  
 STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI-SQUARE P VALUE 
Generic medicines are a copy of original medicines 24,02 0,02 
20-30 6,67 17,78 13,33 44,44 17,78   
31-40 2,44 12,20 18,29 42,68 24,39   
41-50 8,33 11,67 6,67 61,67 11,67   
>50 0,94 4,72 12,26 58,49 23,58   
Generic medicines are interchangeable with original medicines 14,19 0,29 
20-30 0,00 11,11 4,44 57,78 26,67   
31-40 1,20 9,64 14,46 46,99 27,71   
41-50 0,00 10,17 10,17 62,71 16,95   
>50 0,00 5,66 16,98 60,38 16,98   
Generic medicines are therapeutically equivalent to original medicines 17,32 0,14 
20-30 0,00 11,11 13,33 40,00 35,56   
31-40 1,19 3,57 13,10 53,57 28,57   
41-50 3,45 6,90 15,52 56,90 17,24   
>50 0,00 11,43 20,00 48,57 20,00   
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Generic medicines must be in the same dosage form (such as tablet, capsule) as original medicines 18,67 0,10 
20-30 0,00 9,09 6,82 43,18 40,91   
31-40 3,70 14,81 4,94 39,51 37,04   
41-50 1,69 28,81 8,47 42,37 18,64   
>50 4,72 15,09 11,32 43,4 25,47   
Generic medicines are less safe than original medicines 13,13 0,36 
20-30 37,78 51,11 6,67 2,22 2,22   
31-40 36,59 42,68 13,41 6,10 1,22   
41-50 26,67 61,67 8,33 1,67 1,67   
>50 32,38 46,67 18,10 2,86 0,00   
Only those generic medicines which are made by some local reputable manufacturers are safe 27,66 0,01 
20-30 33,33 31,11 22,22 11,11 2,22   
31-40 26,83 29,27 14,63 20,73 8,54   
41-50 15,00 48,33 21,67 10,00 5,00   
>50 14,42 34,62 13,46 31,73 5,77   
Generic medicines are manufactured after the patent expiry of originator/innovator 13,69 0,32 
20-30 2,27 0,00 6,82 47,73 43,18   
31-40 3,61 1,20 3,61 50,60 40,96   
41-50 0,00 1,67 3,33 58,33 36,67   
>50 1,89 5,66 3,77 61,32 27,36   
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Original medicines are of a better quality than generic medicines 14,48 0,27 
20-30 24,44 40,00 26,67 4,44 4,44   
31-40 25,30 32,53 22,89 12,05 7,23   
41-50 16,67 38,33 28,33 15,00 1,67   
>50 13,08 33,64 33,64 16,82 2,80   
Original medicines are required to meet higher safety standards than generic medicine 12,74 0,39 
20-30 22,22 55,56 8,89 11,11 2,22   
31-40 34,15 32,93 8,54 18,29 6,10   
41-50 20,34 47,46 15,25 15,25 1,69   
>50 21,90 46,67 10,48 15,24 5,71   
Original medicines produce fewer side effects than generic medicines 13,14 0,36 
20-30 34,09 50,00 11,36 4,55 0,00   
31-40 34,94 40,96 15,66 7,23 1,20   
41-50 27,12 62,71 6,78 3,39 0,00   
>50 24,76 50,48 19,05 5,71 0,00   
Low-priced medicines are as effective as high-priced medicines 22,52 0,03 
20-30 2,22 8,89 15,56 37,78 35,56   
31-40 0,00 4,82 13,25 44,58 37,35   
41-50 0,00 3,33 21,67 56,67 18,33   
>50 1,90 7,62 27,62 45,71 17,14   
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Table 4.15: Years of experience comparison of Pharmacists knowledge of generic medicines 
STATEMENT LIKERT SCALE  
STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI-SQUARE P VALUE 
Generic medicines are a copy of original medicines   
1-5 7,69 12,82 20,51 38,46 20,51 25,78 0,06 
6-10 4,44 17,78 13,33 46,67 17,78   
11-15 2,13 14,89 8,51 40,43 34,04   
16-20 4,00 4,00 24,00 60,00 8,00   
>20 2,94 6,62 10,29 61,03 19,12   
Generic medicines are interchangeable with original medicines 24,08 0,09 
1-5 0,00 10,26 7,69 58,97 23,08   
6-10 2,22 6,67 13,33 51,11 26,67   
11-15 0,00 10,64 10,64 44,68 36,17   
16-20 0,00 20,00 20,00 52,00 8,00   
>20 0,00 5,88 13,97 62,50 16,91   
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Generic medicines are therapeutically equivalent to original medicines 31,63 0,01 
1-5 0,00 7,69 15,38 41,03 38,46   
6-10 0,00 4,44 15,56 55,56 24,44   
11-15 0,00 8,51 10,64 44,68 38,30   
16-20 8,00 0,00 16,00 64,00 12,00   
>20 0,74 11,03 18,38 50,00 17,65   
Generic medicines must be in the same dosage form (such as tablet, capsule) as original medicines 24,97 0,07 
1-5 0 7,69 7,69 41,03 43,59   
6-10 2,22 20,00 2,22 46,67 24,44   
11-15 4,26 8,51 6,38 36,17 44,68   
16-20 0 24 20 36 20   
>20 4,41 19,85 8,82 42,65 23,53   
Generic medicines are less safe than original medicines 14,73 0,54 
1-5 35,90 51,28 7,69 2,56 2,56   
6-10 40,00 51,11 4,44 4,44 0,00   
11-15 38,30 36,17 17,02 6,38 2,13   
16-20 20,00 60,00 20,00 0,00 0,00   
>20 30,88 50,00 14,71 2,94 0,74   
   
   
 63 
Only those generic medicines which are made by some local reputable manufacturers are safe 20,51 0,20 
1-5 38,46 33,33 17,95 5,13 5,13   
6-10 26,67 24,44 17,78 22,22 6,67   
11-15 21,28 36,17 17,02 21,28 6,38   
16-20 8,00 36,00 28,00 20,00 8,00   
>20 16,18 38,24 13,97 25,00 5,15   
Generic medicines are manufactured after the patent expiry of originator/innovator 37,00 0,002 
1-5 0,00 0,00 10,26 41,03 48,72   
6-10 8,89 2,22 2,22 55,56 28,89   
11-15 4,26 2,13 6,38 40,43 48,94   
16-20 0,00 0,00 0,00 72,00 28,00   
>20 0,00 4,41 2,94 62,50 30,15   
Original medicines are of a better quality than generic medicines 18,74 0,28 
1-5 23,08 41,03 28,21 5,13 2,56   
6-10 22,22 42,22 20,00 8,89 6,67   
11-15 31,91 25,53 25,53 12,77 6,38   
16-20 20,00 36,00 24,00 16,00 4,00   
>20 12,50 34,56 33,82 16,91 2,94   
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Original medicines are required to meet higher safety standards than generic medicine 19,62 0,24 
1-5 20,51 53,85 7,69 15,38 2,56   
6-10 40,00 40,00 6,67 11,11 2,22   
11-15 38,30 27,66 10,64 17,02 6,38   
16-20 20,00 40,00 8,00 20,00 4,00   
>20 17,65 48,53 13,24 15,44 5,15   
Original medicines produce fewer side effects than generic medicines 19,07 0,26 
1-5 30,77 51,28 15,38 2,56 0,00   
6-10 37,78 37,78 11,11 11,11 0,00   
11-15 40,43 38,30 12,77 8,51 2,13   
16-20 28,00 52,00 16,00 0,00 0,00   
>20 22,79 56,62 15,44 4,41 0,00   
Low-priced medicines are as effective as high-priced medicines 29,38 0,02 
1-5 0,00 7,69 17,95 38,46 35,90   
6-10 2,22 2,22 8,89 46,67 40,00   
11-15 0,00 6,38 14,89 42,55 38,30   
16-20 0,00 16,00 16,00 48,00 20,00   




4.2.4 Years of experience comparison of Pharmacists’ knowledge of generic medicines 
Three significant results were found in this comparison (Table 4.15). The first was related to therapeutic 
equivalence of generic medicines. In this question it was interesting to note that while the response rate of 
strong disagreement with the statement that ‘Generic medicines are therapeutically equivalent to original 
medicines’ was below 0,74% in 4 of the years of experience groups, the 16 – 20 years of experience group 
had a response of 8%. Within the >20 years of experience group, there was the lowest agreement rate of 
67,65% compared to the 76 – 83% agreement range in the groups with less experience. 
The second significant finding was related to the manufacturing policy of generic medicines. The statement 
was ‘Generic medicines are manufactured after the patent expiry of originator/innovator’. In this 
comparison, all groups had agreements of >80%. Interestingly, the highest agreement was by pharmacists 
with the greatest experience, with 100% in the 16 – 20 year group and 92,65% in the >20 year group. The 
greatest disagreement was found with 6 – 10 years of experience, (11,11%). In the 1 – 5 and 16 – 20 year 
category no respondents disagreed with this statement. 
 The third significant finding was related to efficacy of medicines. In this question, the statement posed was 
that ‘Low-priced medicines are as effective as high-priced medicines’  The lowest agreement rate in this 
question was found in the 16 – 20 years group (68%) and the >20 years group (65,44%), compared with 
high agreement rates of 80,85% in the 11 – 15 year group and 86,67% in the 6 – 10 year group. A 
significantly high 16% of respondents in the 16 – 20 believed that low-priced medicines are not as effective 
as high- priced medicines. This was much higher than the other groups which whose disagreement response 











Table 4.16: Gender comparison of pharmacists perceptions of generic medicines 
 
STATEMENT 
LIKERT SCALE   
STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI-SQUARE P VALUE 
I believe that locally manufactured medicines are more affordable than original medicines 8,85 0,07 
Male 0,87 10,43 11,30 59,13 18,26   
Female 1,78 10,06 24,85 50,30 13,61   
I believe that locally manufactured medicines are of the same effectiveness as original medicines 3,64 0,46 
Male 0,87 2,61 20,87 57,39 18,26   
Female 0,00 1,78 28,40 55,03 15,38   
I view generic medicines as being of a poorer quality than original medicines 3,07 0,55 
Male 24,35 46,09 20,87 6,96 1,74   
Female 22,49 52,07 21,30 3,55 0,59   
I think generic medicines produce more side effects than original medicines 1,73 0,78 
Male 28,70 51,30 14,78 5,22 0,87   
Female 22,49 57,99 15,38 4,73 0,59   
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I believe low-cost medicines are as safe as high-cost medicines 1,68 0,79 
Male 0,87 3,48 15,65 61,74 19,13   
Female 0,00 4,14 16,57 59,17 20,12   
I believe that multinational products are of a better quality than locally produced products 8,23 0,04 
Male 23,48 48,70 13,91 14,78 0,00   
Female 17,75 44,97 27,81 10,65 0,00   
I believe that the local companies in South Africa are not following Good Manufacturing Practice (GMP) 
guidelines as well as multinationals 
8,21 0,08 
Male 36,52 45,22 14,78 4,35 0,00   
Female 22,49 51,48 22,49 3,55 0,59   
I view few local companies as reputable generic medicine manufacturers 5,92 0,21 
Male 15,65 31,30 11,30 33,04 8,70   
Female 9,47 36,69 18,93 27,81 8,28   
I believe that pharmacists should be educated more about prices of medicines 5,07 0,28 
Male 6,96 20,00 18,26 40,00 14,78   
Female 2,37 15,98 21,89 42,01 18,34   
I believe that generic medicines are only meant for the poor 3,58 0,47 
Male 53,91 39,13 2,61 3,48 0,87   
Female 50,30 46,75 1,78 1,78 0,00   






I think that confidence should be built in the patient about the low-cost brand 4,48 0,35 
Male 2,61 3,48 11,30 53,04 30,43   
Female 0,00 3,55 10,65 55,03 30,77   
Wider use of generic drugs will mean that less money will be used for research and development of new 
pharmaceuticals.  
13,69 0,008 
Male 20,00 33,91 14,78 24,35 6,96   
Female 11,24 41,42 27,81 14,20 5,92   
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4.2.5 Gender comparison of pharmacists’ perceptions of generic medicines 
Two significant results were found in this comparison (Table 4.16). The first was related to the quality of 
multinational vs locally manufactured medicines. Both gender groups had the majority of respondents 
disagreeing with the statement that ‘I believe that multinational products are of a better quality than locally 
produced products’, with a disagreement rate of 72,18% amongst males and a 62,72% disagreement rate 
amongst females. The only significant finding was the high rate of neutral responses in females (27,81%) 
compared to males (13,91%), implying that almost a third of females are unsure of the quality of 
multinational vs locally manufactured medicines.  
The second significant finding was related to the research and development of pharmaceuticals. Both gender 
groups had just over half of respondents disagreeing with the statement that ‘Wider use of generic drugs will 
mean that less money will be used for research and development of new pharmaceuticals’, with a 
disagreement rate of 53,91% amongst males and a 52,66% disagreement rate amongst females. Again there 
was a high rate of neutral responses amongst females (27,81%) compared to males (14,78%). The greatest 





Table 4.17: Pharmaceutical sector comparisons of pharmacists perceptions of generic medicines 
 
STATEMENT 
LIKERT SCALE   
STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI SQUARE P VALUE 
I believe that locally manufactured medicines are more affordable than original medicines 19,87 0,23 
Community Pharmacy 0,93 9,26 16,67 53,7 19,44   
Institutional (Private and 
Public) 
2,78 7,25 22,72 52,78 14,49   




0,00 17,36 5,56 71,53 5,56   
Consultant Pharmacy 0,00 20,00 60,00 20,00 0,00   
I believe that locally manufactured medicines are of the same effectiveness as original medicines 8,94 0,92 
Community Pharmacy 0,93 0,93 30,56 52,78 14,81   
Institutional (Private and 
Public) 
0,00 3,62 19,48 58,33 18,58   




0,00 1,85 34,86 46,53 21,76   
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Consultant Pharmacy 0,00 0,00 40,00 40,00 20,00   
I view generic medicines as being of a poorer quality than original medicines 32,91 0,008 
Community Pharmacy 18,52 49,07 26,85 5,56 0,00   
Institutional (Private and 
Public) 
27,41 47,90 18,79 3,63 2,28   




13,61 54,63 11,81 9,96 0,00   
Consultant Pharmacy 40,00 20,00 0,00 20,00 20,00   
I think generic medicines produce more side effects than original medicines 15,54 0,49 
Community Pharmacy 21,10 53,21 17,43 8,26 0,00   
Institutional (Private and 
Public) 
23,34 55,60 14,47 4,06 2,25   




29,17 63,43 7,41 0,00 0,00   
Consultant Pharmacy 60,00 40,00 0,00 0,00 0,00   
I believe low-cost medicines are as safe as high-cost medicines 12,82 0,69 
Community Pharmacy 0,92 2,75 20,18 58,72 17,43   
Institutional (Private and 
Public) 
0,00 5,88 14,03 59,26 20,84   
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0,00 0,00 7,41 65,28 27,32   
Consultant Pharmacy 0,00 0,00 40,00 60,00 0,00   
I believe that multinational products are of a better quality than locally produced products 17,96 0,12 
Community Pharmacy 16,51 38,53 25,69 19,27 0,00   
Institutional (Private and 
Public) 
17,72 53,05 16,90 12,34 0,00   




50,47 40,97 21,76 11,81 0,00   
Consultant Pharmacy 40,00 40,00 0,00 20,00 0,00   
I believe that the local companies in South Africa are not following Good Manufacturing Practice (GMP) 
guidelines as well as multinationals 
20,84 0,18 
Community Pharmacy 22,94 48,62 24,77 3,67 0,00   
Institutional (Private and 
Public) 
26,34 52,69 17,79 3,19 0,00   




34,72 59,72 3,71 0,00 3,70   
Consultant Pharmacy 40,00 40,00 20,00 0,00 0,00   
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I view few local companies as reputable generic medicine manufacturers 19,51 0,24 
Community Pharmacy 8,26 37,61 22,02 25,69 6,42   
Institutional (Private and 
Public) 
10,89 36,38 13,72 31,77 7,27   




13,66 33,57 16,21 27,32 9,26   
Consultant Pharmacy 50,00 25,00 0,00 25,00 0,00   
I believe that pharmacists should be educated more about prices of medicines 26,23 0,05 
Community Pharmacy 9,17 22,02 22,94 34,86 11,01   
Institutional (Private and 
Public) 
7,29 24,53 18,23 37,70 12,26   




0,00 8,10 25,47 52,78 13,66   
Consultant Pharmacy 0,00 20,00 0,00 80,00 0,00   
I believe that generic medicines are only meant for the poor 10,13 0,86 
Community Pharmacy 45,37 47,22 4,63 1,85 0,93   
Institutional (Private and 
Public) 
49,71 42,53 3,67 3,63 0,47   



















42,13 56,02 0,00 1,85 0,00   
Consultant Pharmacy 80,00 20,00 0,00 0,00 0,00   
   
I think that confidence should be built in the patient about the low-cost brand 12,67 0,70 
Community Pharmacy 1,85 3,70 13,89 56,48 24,07   
Institutional (Private and 
Public) 
0,93 1,85 9,65 62,03 25,55   




6,25 1,85 11,81 45,37 34,72   
Consultant Pharmacy 0,00 0,00 0,00 60,00 40,00   
Wider use of generic drugs will mean that less money will be used for research and development of new 
pharmaceuticals. 
30,58 0,02 
Community Pharmacy 7,41 35,19 22,22 26,85 8,33   
Institutional (Private and 
Public) 
14,52 37,87 17,87 21,54 8,22   




15,51 35,42 29,17 18,06 1,85   
Consultant Pharmacy 40,00 20,00 20,00 0,00 20,00   
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4.2.6 Pharmaceutical sector comparisons of pharmacists’ perceptions of generic medicines 
Three significant results were found in this comparison (Table 4.17). The first was related to the quality of 
generic medicines. The statement presented to pharmacists was that ‘I view generic medicines as being of a 
poorer quality than original medicines’.  Significant findings were found amongst academic and consultant 
pharmacists. 88,24% of academic pharmacists disagreed with the statement compared to a mere 45,93% of 
community pharmacists. A significantly high number of consultant pharmacists (40%) believed that generic 
medicines are of a poorer quality than original medicines. This was much higher than the other groups 
which ranged from 0% of academic pharmacists to 9,96% of wholesale & manufacturing pharmacists. 
The second was related to education of pricing. Significant findings were found amongst wholesale and 
manufacturing pharmacists as well as consultant pharmacists. 80% of consultant pharmacists agreed with 
the statement that ‘I believe that pharmacists should be educated more about prices of medicines’, while less 
than half (45,87%) of community pharmacists agreed that pharmacists require more education on pricing of 
medication. Almost a third of community and institutional pharmacists disagreed with this statement 
compared to only 8,10% of manufacturing pharmacists. 
The third was related to the research and development of pharmaceuticals. The most significant finding in 
this question was in the academic institution category. 82,35% of academic pharmacists disagreed with the 
statement that ‘Wider use of generic drugs will mean that less money will be used for research and 
development of new pharmaceuticals.’ Compared to a range of disagreement from 42,6% amongst 
community pharmacists to 60% amongst consultant pharmacists. More than a third of Community 






Table 4.18: Age category comparison of pharmacists perceptions of generic medicines 
 
STATEMENT 
LIKERT SCALE   
STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI SQUARE P VALUE 
I believe that locally manufactured medicines are more affordable than original medicines 10,43 0,58 
20-30 2,33 11,63 25,58 39,53 20,93   
31-40 2,47 11,11 22,22 46,91 17,28   
41-50 1,70 8,48 15,25 62,71 11,86   
>50 0,00 9,80 16,67 59,8 13,73   
I believe that locally manufactured medicines are of the same effectiveness as original medicines 17,30 0,14 
20-30 0,00 2,33 20,93 62,79 13,95   
31-40 0,00 2,50 20,00 51,25 26,25   
41-50 1,69 0,00 22,03 62,71 13,56   
>50 0,00 2,91 33,01 52,43 11,65   
I view generic medicines as being of a poorer quality than original medicines 22,99 0,03 
20-30 26,19 66,67 4,76 2,38 0,00   
31-40 31,25 43,75 17,50 7,50 0,00   
41-50 18,64 55,93 20,34 3,39 1,70   
>50 18,45 43,69 31,07 4,85 1,94   
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I think generic medicines produce more side effects than original medicines 14,99 0,24 
20-30 25,58 62,79 6,98 4,65 0,00   
31-40 32,93 47,56 12,20 7,32 0,00   
41-50 22,03 61,02 11,86 3,39 1,70   
>50 19,42 53,40 22,33 3,88 0,97   
I believe low-cost medicines are as safe as high-cost medicines 14,45 0,27 
20-30 0,00 6,98 13,95 55,81 23,26   
31-40 1,23 3,70 13,58 54,32 27,16   
41-50 0,00 0,00 13,56 67,80 18,64   
>50 0,00 4,90 20,59 61,76 12,75   
I believe that multinational products are of a better quality than locally produced products 16,18 0,07 
20-30 18,60 48,84 30,23 2,33 0,00   
31-40 24,39 51,22 13,41 10,98 0,00   
41-50 18,64 50,85 15,25 15,25 0,00   
>50 17,48 37,86 29,13 15,53 0,00   
I believe that the local companies in South Africa are not following Good Manufacturing Practice (GMP) 
guidelines as well as multinationals 
20,1 0,07 
20-30 28,57 50,00 16,67 4,76 0,00   
31-40 41,46 35,37 17,07 6,10 0,00   
41-50 23,73 55,93 16,95 1,69 1,69   
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>50 19,42 54,37 23,30 2,91 0,00   
I view few local companies as reputable generic medicine manufacturers 16,44 0,17 
20-30 11,63 27,91 11,63 39,53 9,30   
31-40 14,63 25,61 19,51 26,83 13,41   
41-50 16,95 40,68 11,86 23,73 6,78   
>50 6,86 40,20 16,67 31,37 4,90   
I believe that pharmacists should be educated more about prices of medicines 30,4 0,002 
20-30 0,00 6,98 13,95 55,81 23,26   
31-40 4,94 12,35 13,58 40,74 28,40   
41-50 3,39 23,73 23,73 37,29 11,86   
>50 5,88 22,55 26,47 37,25 7,84   
I believe that generic medicines are only meant for the poor 10,98 0,53 
20-30 55,81 41,86 2,33 0,00 0,00   
31-40 57,32 39,02 0,00 3,66 0,00   
41-50 49,15 45,76 1,69 1,69 1,69   
>50 46,53 46,53 3,96 2,97 0,00   
I think that confidence should be built in the patient about the low-cost brand 17,70 0,13 
20-30 2,33 2,33 6,98 41,86 46,51   
31-40 1,22 2,44 8,54 50,00 30,51   
41-50 0,00 3,39 10,17 55,93 30,51   
 79 
>50 0,99 4,95 14,85 61,39 17,82   
Wider use of generic drugs will mean that less money will be used for research and development of new 
pharmaceuticals. 
23,48 0,02 
20-30 18,60 37,21 34.88 6,98 2,33   
31-40 18,52 39,51 18,52 17,28 6,17   
41-50 20,34 45,76 13,56 16,95 3,39   
>50 6,86 33,33 25,49 24,51 9,80   
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4.2.7 Age category comparison of pharmacists’ perceptions of generic medicines 
Three significant results were found in this comparison (Table 4.18). The first was related to the quality of 
generic medicines. The statement presented to pharmacists was that ‘I view generic medicines as being of a 
poorer quality than original medicines’.  The most significant finding within this question was amongst 
pharmacists between the ages of 20 – 30 years. Almost all of the youngest pharmacists (92,86%) disagreed 
with this statement. This was significantly higher than the other groups which ranged from 62,14% amongst 
pharmacists >50 years of age to 74,57% amongst pharmacists in the 41 – 50 age category. 
The second was related to education of pricing. The statement presented to pharmacists was that ‘I believe 
that pharmacists should be educated more about prices of medicines.’ The most significant finding within 
this question was again amongst pharmacists in the 20 -30 age group. Almost 80% of pharmacists within 
this category agreed that pharmacists require more education on pricing. This was significantly higher than 
the other groups which ranged from 45,09% amongst pharmacists >50 years of age to 69,14% amongst 
pharmacists in the 31 – 40 age category. 
The third was related to research and development of pharmaceuticals. The most significant finding in this 
question was amongst pharmacists >50 years of age. More than a third (34,31%) of pharmacists in this 
category agreed with the statement that ‘Wider use of generic drugs will mean that less money will be used 
for research and development of new pharmaceuticals.’ Compared to a range of agreement from 9,31% 
amongst pharmacists in the 20 – 30 year age group to 23,45% amongst pharmacists in the 31 – 40 year age 
group. Almost two thirds (66,1%) of pharmacists in the 41 – 50 year age category believed that usage of 
generics does not hamper research and development of pharmaceuticals compared to just 40% of 
pharmacists in the >50 years age group. 
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Table 4.19: Years of experience comparison of pharmacists perceptions of generic medicines 
 
STATEMENT 
LIKERT SCALE   
STRONGLY 
DISAGREE 
DISAGREE NEUTRAL AGREE STRONGLY 
AGREE 
CHI SQUARE P VALUE 
I believe that locally manufactured medicines are more affordable than original medicines 13,20 0,66 
1-5 2,70 8,11 27,03 43,24 18,92   
6-10 4,44 8,89 24,44 46,67 15,56   
11-15 0,00 10,87 15,22 52,17 21,74   
16-20 0,00 16,00 20,00 48,00 16,00   
>20 0,76 9,85 16,67 59,85 12,12   
I believe that locally manufactured medicines are of the same effectiveness as original medicines 25,67 0,06 
1-5 0,00 0,00 27,03 56,76 16,22   
6-10 0,00 2,22 6,67 68,89 22,22   
11-15 0,00 6,67 2,22 42,22 28,89   
16-20 0,00 0,00 32,00 56,00 12,00   
>20 0,76 1,52 3,30 56,06 11,36   
I view generic medicines as being of a poorer quality than original medicines 30,61 0,02 
1-5 27,03 59,46 10,81 0,00 0,00   
6-10 26,67 60,00 4,44 4,44 2,22   
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11-15 36,96 30,43 21,74 10,87 0,00   
16-20 20,00 48,00 28,00 4,00 0,00   
>20 16,67 49,24 28,03 4,55 1,52   
I think generic medicines produce more side effects than original medicines 20,78 0,19 
1-5 27,03 62,16 8,11 2,70 0,00   
6-10 26,67 57,78 6,67 8,89 0,00   
11-15 38,30 38,30 17,02 6,38 0,00   
16-20 16,00 60,00 16,00 4,00 4,00   
>20 19,70 56,82 18,94 3,79 0,76   
I believe low-cost medicines are as safe as high-cost medicines 18,72 0,28 
1-5 0,00 2,70 16,22 56,76 24,32   
6-10 2,22 4,44 8,89 57,78 26,67   
11-15 0,00 6,52 15,22 47,83 30,43   
16-20 0,00 4,00 24,00 56,00 16,00   
>20 0,00 3,03 17,42 65,91 12,88   
I believe that multinational products are of a better quality than locally produced products 12,21 0,43 
1-5 16,22 51,35 27,03 5,41 0,00   
6-10 20,00 51,11 22,22 6,67 0,00   
11-15 29,79 44,68 12,77 12,77 0,00   
16-20 20,00 40,00 32,00 8,00 0,00   
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>20 17,42 43,94 21,97 16,67 0,00   
I believe that the local companies in South Africa are not following Good Manufacturing Practice (GMP) 
guidelines as well as multinationals 
21,65 0,15 
1-5 29,73 51,35 16,22 2,70 0,00   
6-10 35,56 33,33 20,00 8,89 0,00   
11-15 12,77 21,28 17,02 2,13 0,00   
16-20 24,00 40,00 32,00 4,00 0,00   
>20 21,21 57,58 18,94 1,52 0,76   
I view few local companies as reputable generic medicine manufacturers 15,86 0,46 
1-5 16,22 29,73 18,92 29,73 5,41   
6-10 8,89 22,22 17,78 40,00 11,11   
11-15 19,15 34,04 10,64 23,40 12,77   
16-20 4,00 36,00 24,00 24,00 12,00   
>20 10,61 39,39 13,64 29,55 6,06   
I believe that pharmacists should be educated more about prices of medicines 28,23 0,03 
1-5 0,00 10,81 18,92 45,95 24,32   
6-10 2,22 8,89 8,89 53,33 26,67   
11-15 8,70 17,39 17,39 36,96 19,57   
16-20 0,00 20,00 20,00 36,00 24,00   
>20 5,30 21,97 25,76 37,88 8,33   
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I believe that generic medicines are only meant for the poor 10,28 0,85 
1-5 56,76 43,24 0,00 0,00 0,00   
6-10 60,00 35,56 2,22 2,22 0,00   
11-15 55,32 42,55 0,00 2,13 0,00   
16-20 40,00 56,00 0,00 4,00 0,00   
>20 46,97 43,94 3,79 3,03 0,76   
I think that confidence should be built in the patient about the low-cost brand 26,75 0,04 
1-5 0,00 2,70 8,11 40,54 48,65   
6-10 4,44 2,22 4,44 46,67 42,22   
11-15 0,00 6,38 8,51 48,94 36,17   
16-20 0,00 0,00 12,00 60,00 28,00   
>20 0,76 3,79 14,39 59,85 19,70   
Wider use of generic drugs will mean that less money will be used for research and development of new 
pharmaceuticals. 
28,50 0,03 
1-5 16,22 37,84 37,84 5,41 2,70   
6-10 20,00 28,89 28,89 20,00 2,22   
11-15 19,57 47,83 6,52 15,22 10,87   
16-20 20,00 44,00 12,00 24,00 0,00   
>20 9,85 36,36 23,48 21,21 8,33   
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4.2.8 Years of experience comparison of pharmacists’ perceptions of generic medicines 
Four significant results were found in Table 4.19. The first was related to the quality of 
generic medicines. The statement presented to pharmacists was that ‘I view generic medicines 
as being of a poorer quality than original medicines’.  86% of pharmacists with 1 – 5 and 6 – 
10 years of experience disagreed with this statement. This was significantly higher than the 
larger age groups with just 66% disagreeing in the >20 years’ experience category, 67% in 
the 11 – 16 year category and 68% in the 16 – 20 year category. More than 10% of 
pharmacists in the 11 – 15 years of experience category believed that generics are of a poorer 
quality than originals, whilst there was a zero agreement response amongst the youngest 
pharmacists. 
The second was related to education of pricing. Significant findings were found amongst 
pharmacists in the 6 – 10 years of experience category as well as the >20 years of experience 
category. 80% of pharmacists with 6 – 10 years of experience agreed with the statement that 
‘I believe that pharmacists should be educated more about prices of medicines’, while less 
than half (46,21%) of pharmacists with >20 years of experience agreed that pharmacists 
require more education on pricing of medication.  
The third was related to confidence in generics. The statement presented to pharmacists was 
that ‘I think that confidence should be built in the patient about the low-cost brand.’ 
Significant findings were found amongst pharmacists in the 1 – 5 years of experience 
category and the 16 – 20 years of experience category. Almost 90% of pharmacists with the 
least number of years of experience agreed with this statement compared to less than 80% of 
pharmacists with the greatest number of years of experience. There was a zero disagreement 
response rate amongst pharmacists in the 16 – 20 years of experience category.  
The fourth was related to research and development of pharmaceuticals. The most significant 
finding in this question was amongst pharmacists with 1 - 5 years of experience. 8,11% of 
pharmacists in this category agreed with the statement that ‘Wider use of generic drugs will 
mean that less money will be used for research and development of new pharmaceuticals.’ 
This was significantly lower compared to the other groups which ranged from 22,22% 
amongst pharmacists with 6 – 10 years of experience to 29,54% amongst pharmacists with > 
20 years of experience. More than a third (37,84%) of the youngest pharmacists had a neutral 
response to this statement compared to just 6,52% of pharmacists in the 11 – 16 years of 
experience category  
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CHAPTER 5: DISCUSSION 
Generic medicine usage has increased significantly in recent years, due to their lower cost. 
Through their use, healthcare expenditure can be reduced and this is greatly beneficial to 
developing countries like South Africa where cost saving strategies are vital for the economy.  
There are only a few studies that have explored the perceptions and views of pharmacists 
towards generic medicine use. Therefore, in this study, we aimed to evaluate the views, 
knowledge and perception of pharmacists about generics. Most pharmacists seemed well 
informed and confident in the use of generic medication. More than 70% of respondents 
believed that generic medicines are therapeutically equivalent, equally safe and 
interchangeable with their original counterparts, yet only half believed that generic medicines 
were of the same quality as original medications. Many believed that this was due to original 
medications having stricter safety standards. Although South African regulating bodies 
ensure optimal safety and efficacy of all medicines are maintained through stringent quality 
inspections, some substandard medicines have entered the market as in the case of the 
Tuberculosis generic medications that were removed from the market in 2008. These findings 
can lead to doubts in the confidence of pharmacists towards generic medicines. Efforts 
should be made to improve the functioning of the MCC and ensure that all medicines are 
assessed according to international standards prior to registration as well as ongoing post 
market evaluations carried out to prevent defects in medicine batches. 
Generally, it was found that respondents were supportive of generic medicines; however, 
many believe that generic substitution is not suitable all the time. Several pharmacists 
reported that consumers experienced therapeutic nonequivalence following generic 
substitution. Patients’ lack of confidence in generic medications relating to efficacy and 
safety was also a problem encountered, yet only 14% of pharmacists would take the time to 
educate and persuade the patient to use a generic instead. If consumers are educated 
sufficiently on generic substitution and its benefits, they may be more accepting of these 
agents.  
The majority of respondents believed that generic medicines are cost-effective with more 
than 90% of pharmacists citing cost to customers as a reason for them recommending a 
generic alternative. “Medical Scheme requirement” was also a major influence for 
pharmacists to practice generic substitution. The Mediscor Medicines Review reported that in 
2010, 50% of patients in South Africa that are insured with medical aid schemes, prefer to 
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use generic medicines when they are available, (12) which is an increase from 48,8% in 2009. 
The South African Government has implemented a strict legislation on pricing in order to 
reduce the high cost of healthcare in the country. Policies obliging pharmacists to offer and 
dispense more affordable generic alternatives to their customers have also been implemented. 
 
5.1 Comparison of study with International studies 
 
5.1.1 Bioequivelance 
A study, conducted in Ireland by Dunne et al (2013), revealed that pharmacists in Ireland 
were more trusting toward generic medicines compared to those in the Western Cape. (64) In 
Ireland, 98% of pharmacists believed that generics are similar to originals, compared to 74% 
of Western Cape respondents that agreed that generic and original medicines are 
therapeutically and biologically equivalent. Results from a study conducted by Babar et al, in 
New Zealand (2010), were similar with approximately 70% of respondents believing that a 
generic medicine is bioequivalent to the original brand medicine. (50) In Malaysia, a similar 
study was conducted by Chong et al. (52) A comparison of this study revealed that Malaysian 
pharmacists were less trusting of generic medicines than Western Cape pharmacists with only 
50% of Malaysian pharmacists believing that generic medicines are therapeutically 
equivalent to originals. (52) This is similar to a study in Jamaica by Gossell-Williams (2005) 
where physicians were questioned on whether generics and original medicines were bio-
equivalent. (54) There was equal distribution between agreement and disagreement with this 
statement suggesting lack of confidence in the performance of the generics available in 
Jamaica and Malaysia. 
 Comparisons within current study: 
Almost a quarter of respondents in the 20 -30 age group disagreed with the statement that 
‘generics medicines are a copy of original medicines’ (p = 0,02). Generic medicines are in 
fact bio-identical to their original counterparts with regard to use, dosage, strength, route of 
administration, safety, quality and side effects. This misconception amongst the group of 
pharmacists that should be most well informed about generics due to their recent graduation 
needs to be addressed. These are the pharmacists of the future that are responsible for 
providing cost effective healthcare and rational medicine use to patients. They are integral in 
promoting generic medicine use and educating patients and other healthcare workers about it.   
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5.1.2 Cost Effectiveness 
The results of this study do bear similarities to other international studies. Pharmacists in the 
New Zealand study and the Western Cape had similar views on the cost efficacy of generic 
medicines, with 70% of New Zealand respondants (50) and 73% of Western Cape respondants 
citing cost effectiveness as being a reason for recommending generic medicines. The cost of 
generics versus the original medicine was also shown to be a major factor in the acceptance 
of generics by physicians in Jamaica (54) No significant differences in opinions between 
categories of Western Cape pharmacists were found in this study as there was a general 
consensus that generic medicines are more cost effective. 
 
5.1.3 Therapeutic Efficacy 
Half of the New Zealand respondents believed that the original brands are more effective 
than generic medicines. (50) This study, however, revealed more positive findings with 72% of 
Western Cape pharmacists proclaiming no difference in efficacy between generic and 
original medicines. In Ireland, however, 96% of pharmacists believed that generics are as 
effective as their original counterparts implying that health professionals have very positive 
outlooks on generic medicines in this country. (64) 
 Comparisons within current study: 
More than a third of pharmacists over the age of 50 (62,85%) were doubtful about the 
efficacy of low priced medicines compared to high priced medicines. This was sigificantly 
higher than in the younger age categories (p = 0,03). These findings mirrored that of the years 
of experience category where there was more than a 25% difference in the agreement rate 
between the most experienced pharmacists and those in the 11 – 15 year group (p = 0,02). 
This misconception could be due to older pharmacists having previous experiences of low 
quality medicine. However, currently the MCC ensures that all medication, regardless of its 
price abides by the same safety and efficacy standards. 
Within the >20 years of experience group, only 67,65% of pharmacists agreed that ‘Generic 
medicines are therapeutically equivalent to original medicines’ compared to the 76 – 83% 
agreement range in the groups with less experience. It is evident that a pharmacist’s length of 
time in practice significantly influences their knowledge of generic medicines (p = 0,01) The 
study carried out in New Zealand also found that pharmacists with a shorter length of time in 
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practice had a better understanding of generic medicines as compared to more experienced 
pharmacists. (p = 0,03) According to an article by Woolston C (2015), which discussed the 
History of Generic Medcines, he noted that as recently as 40 years ago, medication 
manufacturing companies could release new products onto the market with far less testing 
than is required today. (65) The medicine's safety and effectiveness was only determines came 
after it became available to the market. An example of this dangerous approach was when the 
sedative thalidomide caused thousands of devastating birth defects around the world and was 
then only removed off the shelves. (65)  
 
5.1.4 Quality 
Pharmacists in the Western Cape appear to have greater trust in the quality of generic 
medicines, with only 17% believing that original medicines were of a higher quality than 
generics. In New Zealand, however, 65% of respondents suggested the original medicines are 
of a higher quality than generic medicines. (50) 21% of Malaysian pharmacists believed that 
generics were inferior in quality to original medicines. (52) 
 Comparisons within current study 
In this study, findings relating to the quality of multinational versus locally manufactured 
medicines between the genders revealed that males appeared slightly more informed on the 
equal quality of both products, with a 10% higher disagreement rate to the statement that ‘I 
believe that multinational products are of a better quality than locally produced products’, (p 
= 0,04)   
The statement relating to the quality of generic medicines compared to originals revealed 
very significant findings. 40% of consultant pharmacists believed that generic medicines are 
of a poorer quality compared to 0% of academic pharmacists (p = 0,008). It can be assumed 
that academic pharmacists have better knowledge and expertise regarding the MCC’s 
stringent quality testing of all medicines whether generic or original. 
Almost all pharmacists (92,86%) in the 20 – 30 year age group compared to only 62% in the 
>50 year group did not view generic medicines as being of a poorer quality than original 
medicines (p = 0,03). It can be assumed that the youngest pharmacists, having been exposed 
to most recent research on the stringent quality and efficacy of generic medicines are 
therefore more confident in them. Years of experience results mirrored these findings with a 




This study provided positive feedback on pharmacists’ knowledge of safety of generic and 
original medicines, with only 4% of respondents believing that original medicines were safer 
than their generic counterparts and 20% believing that original medicines are required to 
meet higher safety standards than their original counterparts. In New Zealand, however, 
almost a third (28%) of pharmacists mentioned that original brands were safer than generics. 
(50) A high 80% of pharmacists in the Western Cape disagreed that generic medicines produce 
more side effects than original medicines, compared to a 62% disagreement rate by 
Malaysian pharmacists implying that hesitancy still remains in Malaysia regarding generic 
medicine usage do to a negative outlook on the side effect profile of these medicines. (52) 
 Comparisons within current study: 
The misconceptions relating to safety of generics was particularly evident in the results from 
Table 17, where it was noted that the majority of consultant pharmacists strongly believed 
that original medicines are required to meet higher safety standards than generics (p = 0,005). 
More than a third of respondents in the >50 age group agreed with the statement that ‘Only 
those generic medicines which are made by some local reputable manufacturers are safe’. (p 
=0,01) These statements are incorrect as the MCC has the same stringent regulations and 
qualities testing of generics as original medicines and all manufacturers have to abide by 
these regulations. These findings are a cause for concern as the main role of consultant 
pharmacists is to promote Health Care Improvement through managed health care, with the 
emphasis on health education and medicine intervention. Their aim is give the patient the 
best, but also the safest and most cost effective medication therapy. Consultant therapists are 
therefore integral in promoting generic medicines. However, if they have misconceptions 
regarding the safety of generics, this may hinder their promotion of generic medicines. 
5.1.6 Education 
Pharmacists in both Ireland and the Western Cape were not keen on educating patients on 
generic usage with 21% of pharmacists in Ireland encouraging generic use and only 14% in 
the Western Cape. (64) 
 Comparisons within current study 
80% of consultant pharmacists compared to just 45,87% of community pharmacists agreed 
with the statement that ‘I believe that pharmacists should be educated more about prices of 
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medicines.’ (p = 0,05) It is important for pharmacists to have adequate knowledge on the 
prices of medicines so that they choose the most cost effective treatment for patients. 
Community pharmacists in particular have a vital role in ensuring rational medicine usage 
and the importance of this role should be brought to their attention.  
Almost 80% of pharmacists in the 20 – 30 age group believed that pharmacists should be 
educated more about prices of medicines. This was significantly higher than the oldest 
pharmacists where only 45% felt the same way (p = 0,002). Similar results were found in the 
years of experience category (p = 0,03). A theory for these results is that the younger 
pharmacists are more keen on learning and improving there knowledge on medicine pricing. 
Whereas older pharmacists who have more experience with the medicines available are 
already familiar with medicine prices and do not feel the need for further education. 
Almost 90% of pharmacists with the least number of years of experience compared to less 
than 80% of pharmacists with the greatest number of years of experience agreed that 
confidence should be built in the patient about the low-cost brand (p = 0,04). Although these 
findings were not vastly different, it was interesting to note that the newer pharmacists were 
more concerned about rational medicine use and promoting the use of safe and effective 
medicines at the lowest possible cost. This is important in reducing the financial burden of 
the high cost of healthcare in the country. 
The link between experience and knowledge was not true for all statements however, as it 
was seen when the statement that ‘Generic medicines are manufactured after the patent 
expiry of originator/innovator’ was discussed. In this comparison, the highest agreement 
(100%) was by pharmacists with the greatest experience (p = 0,002). This implies that the 
more experienced pharmacists had a better understanding of the manufacturing protocol of 
generic medicines.   
 
5.1.7 Research 
When the statement that ‘Wider use of generic drugs will mean that less money will be used 
for research and development of new pharmaceuticals’, significant findings were obtained 
through various comparisons. Almost a third of males in this study agreed with this 
statement, an 11% higher response rate than females (p = 0,008). In another comparison, 
more than 80% of academic pharmacists compared to only 42,6% of community pharmacists 
agreed with the statement (p = 0,02). Being directly involved in research and development of 
new pharmaceuticals, it is not surprising that academic pharmacists had the greatest positive 
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response. More than a third (34,31%) of pharmacists in the >50 year age category agreed.’ 
This was significantly higher than the 9,31% agreement amongst pharmacists in the 20 – 30 
year age group (p = 0,02). Although medicine discovery is a complex, high risk and high cost 
endeavour, older pharmacists should be informed about the benefits of research into new 
medicines especially those in the treatment of chronic diseases. 
According to a statement by Stiglitz J (2006), a former World Bank chief economist, 
medicine companies in developing countries spend more on advertising and marketing than 
on research. More research is carried out on lifestyle drugs than on life saving medicines, and 
almost nothing on diseases that affect developing countries only. (66) This is because the poor 
population cannot afford medicines, and medicine companies make investments that yield the 
highest returns. (66)  
 
5.2 Role of health professionals 
Health professionals, especially general practitioners (GP), can greatly influence consumers’ 
acceptance of generic medicines as great trust is placed in their expertise and knowledge. In 
this survey a few pharmacists indicated that consumers preferred to check with their GP 
before using a generic medicine despite them being aware that the generic medicine 
contained the same ingredients as the branded medicine. In order to promote the use of 
generic medicines by consumers, it would be beneficial for prescribers to mention that a 
generic brand might be offered by the pharmacist when they collect their medication. If the 
brand substitution is acceptable to the prescriber, this brief advice and reassurance may be 
enough to secure the patients trust in generic medicines. 
Pharmacists play an integral role in the provision of education to consumers regarding the 
efficacy and safety of generic medicines. If consumers are satisfied with the quality of 
information received from Health professionals, they will be more accepting of generic 
medicines. However, in order for consumers to have greater trust in generics, pharmacists 
need to have confidence in their safety and efficacy. Strategies aimed at educating 
pharmacists and dispelling doubts regarding the quality control testing of these medications is 
important in order to increase generic substitution in South Africa. In this study, a number of 
pharmacists commented that more training and guidance on generic medicines should be 
aimed at pharmacists. 
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5.3 Areas for future research 
 
Generic medicines are a vital component of South Africa’s health care system; however, 
much research is still required on the full impact of the use of generic medicines. By 
exploring pharmacists’ perceptions and knowledge of generic medicines, we can move 
toward understanding the use of generics and their likely impact and influence it may have on 
patient compliance.  
Due to the relevance of this topic throughout South Africa, the survey can be expanded to 
other parts of the country in order to draw more accurate generalisation of the results. These 
findings should be of great interest to pharmacists and other health professionals and 
especially to the government. It will enable them to develop and implement strategies to 
improve patient’s knowledge and views of generic medicines, with pharmacists being the key 
health professionals likely to positively influence patients’ decisions. The data obtained from 
this study provides a base on which to develop, implement, and evaluate primary care 
interventions. This can be used in order to provide accurate information and create awareness 
amongst the public regarding generic medicines (50) Further studies focusing on patient 
perceptions, generic substitution policies, as well as the impact of biologicals on medicine 
usage in South Africa are required in order to improve rational medicine usage in the country 
and provide patients with the best treatment options available.  
 
5.4 Limitations of the Study 
 Although the required sample size was reached, the low response rate may have 
yielded unreliable data. A bigger sample size is required to make accurate and valid 
associations between variables such as gender, age and years of experience. 
 The survey was limited to Western Cape pharmacists, and therefore is not a true 
reflection of the opinions of  all South African pharmacists. The survey would need to 
be expanded nationally in oreder to make generalised comments. 
 The reliability of the survey data may be unclear as answer options such as ‘strongly 
agree’ or ‘neutral’ may be interpreted differently by respondents.  
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 Subjective surveys can influence respondents to provide answers that present 




CHAPTER 6: CONCLUSION 
The purpose of promoting the use of generic medicines extends beyond the curbing of 
medical expenses. The ultimate aim is to try to provide all South African citizens with 
medical services that are inexpensive, effective, safe and of a high quality by effectively 
utilising the limited healthcare resources available. In order to increase the use of the generic 
medicines, it is important to continue efforts aimed at securing patients and health 
professionals’ trust in the quality and efficacy of generic medication through the provision of 
information. Furthermore, it is important to raise awareness about these medications amongst 
healthcare professionals and patients in order for them to gain confidence in generic 
medicines and increase their willingness to actively use generic medicines.  
From the results, it can be seen that like consumers, some pharmacists maintain erroneous 
beliefs about generic prescription medication. For instance, even though the MCC states that 
generic medication must be therapeutically equivalent to brand name medication, many 
pharmacists still remain doubtful about the quality, stable supply, and information available 
on generic medicines. To correct these misperceptions and encourage generic substitution, 
health organisations should implement education strategies targeting prescribers and 
pharmacists.  
Pharmacists’ play an integral role in encouraging generic medication use by consumers and 
efforts to increase generic medication use directed at pharmacists should be maintained. (67) 
Medicine expenditure can therefore be reduced and access to precious resources can be 
increased, in order to meet the urgent health care needs within South Africa. (68) In light of 
this, the present study was aimed at shedding some insight into the confidence that 
pharmacists have in generic medication. They have a strong influence on consumers’ 
perception of generic medication and choice of medication so these results can be used to 
implement educational campaigns aimed at health professionals as well as create awareness 
amongst consumers, and perhaps input into undergraduate curriculum for more knowledge 




CHAPTER 7: RECOMMENDATIONS 
The provision of explanation by pharmacists and other healthcare workers, as well as 
advertisements on generic medication will strongly influence patients’ motivations to change 
to generic medications. 
 As a means to improve the provision of information on generic medication, medicine 
information sheets should be handed to patients when pharmacists are dispensing. 
This should include information on availability of generic medication as well as 
prices and an inventory. (69) 
 Governments should improve awareness by implementing campaigns (pharmacy 
awareness week) and direct-marketing, targeting the public on the use of generic 
medication as well as improve the training of pharmacists (undergraduate level) on 
the importance of generic substitution as well as provide guidance to them. (69) 
 Mass educational efforts (radio and television campaigns) aimed at increasing 
consumers’ knowledge and attitudes toward generics should be implemented in order 
to encourage them to play an active role in managing their medical conditions. 
Through the provision of accurate and informative advice those with low levels of 
literacy will be able to overcome their misconceptions about generic medicines. (9) 
 Policymakers and researchers should address the questions surrounding the 
therapeutic equivalences of generic medication, to both pharmacists and patients 
 In addition, given the complexity of the health care system, it is likely that a number 
of generic policies will have to be combined in a more comprehensive approach 
before generic medication utilisation can be maximised. (69) 
 Researchers should make greater efforts towards studying consumer’s decision‐
making processes and the factors influencing it. 
 The communication and quality of information provided between patients and health 
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APPENDIX A : QUESTIONNAIRE 
 
EXPLORING PHARMACISTS VIEWS, KNOWLEDGE AND 





My name is Naseema Shaikh, a Masters Student from the University of KwaZulu-Natal.  
 
You are invited to participate in a research study conducted by the University of KwaZulu-
Natal. Your participation is strictly voluntary. Before agreeing to participate, you should 
know enough about it to make an informed decision. If you have any questions, please ask 
and be sure you are satisfied with the answers before participating.  
 
The purpose of this study is to explore pharmacists’ views, knowledge and perception 
regarding generic medicines in Western Cape. This will involve evaluating pharmacists' 
perceptions, views, and knowledge of and willingness to recommend generic medicines as 
well as exploring their perceptions of the safety, quality, and efficacy of generic medicines 
and views on current policy with respect to substitution of generic medicines.  
 
The aim is to encourage the use of generic medication and gain wider health professionals’ 
support for the quality utilization of generic medicines. Participation in this study will be the 
completion of the electronic questionnaire and forwarding of the completed survey to the 
researcher. This data will then be used to draw conclusions relating to the subject matter. 
 
There are no known risks associated with this research project other than possible discomfort 
with the following:  
 
• You will be asked to be completely honest about yourself when completing the form.  
• You will be asked questions about personal experiences relating to generic medications 
whilst working as a pharmacist as well as your opinions and views relating to the topic 
 
Possible benefits from participation in this project are:  
 
• You will have an opportunity to reflect on your experiences.  
• You will contribute to our knowledge about the views, and perceptions regarding generic 
medicines which may be extrapolated to other parts of the country.  
• This data can assist researchers to identify any misconceptions relating to generic 
medications and implement initiatives aimed at encouraging the use of generic medication by 
health professionals  
 
This study has been ethically reviewed and approved by the UKZN Biomedical research 
Ethics Committee (approval number BE317/14). 
 
Remember, participation is voluntary. You may choose not to participate, and you may 
withdraw at anytime during the research project. In addition, you may choose not to answer 
any questions with which you are not comfortable. You will NOT be penalized in any way 
should you choose not to participate or to withdraw.  
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We will do everything we can to protect your privacy. As part of this effort, your identity will 
not be revealed in any publications that result from this study. The information in the study 
records will be kept strictly confidential. Individual data will be stored securely and will be 
made available only to persons conducting the study. No reference will be made in oral or 
written reports that could link you to the study. 
 
In the event of any problems or concerns/questions you may contact the researcher at: 
Cellphone – 0723734475 
Email – naseema_1@yahoo.com 
 
Or the supervisor (Prof Fatima Suleman) at sulemanf@ukzn.ac.za 
 
or the UKZN Biomedical Research Ethics Committee, contact details as follows:  
 
BIOMEDICAL RESEARCH ETHICS ADMINISTRATION 
Research Office, Westville Campus 
Govan Mbeki Building 
Private Bag X 54001  
Durban  
4000 
KwaZulu-Natal, SOUTH AFRICA 






















1. I have been informed of the following (tick all that are relevant) 
 
2. Agreement to Participate in Study 
 Agreement to Participate in Study   
I agree to participate 













 I have been informed about the study entitled “Exploring pharmacists’ views,  
knowledge and perception regarding generic medicines in Western Cape” by Naseema  
Shaikh 
 I understand the purpose and procedures of the study 
 I have been given an opportunity to answer questions about the study and have had  
answers to my satisfaction. 
 I declare that my participation in this study is entirely voluntary and that I may  
withdraw at any time without affecting any treatment or care that I would usually be  
entitled to. 
 If I have any further questions/concerns or queries related to the study I understand that  
I may contact the researcher via email or telephone 
 If I have any questions or concerns about my rights as a study participant, or if I am  
concerned about an aspect of the study or the researchers then I may contact BREC or  
















WHAT BASIC PHARMACEUTICAL QUALIFICATION DO YOU POSSESS? 
 
 









20 - 30 31 – 40 41 - 50 > 50 
    
MALE FEMALE 
  




   
1 - 5 6 – 10 11 - 15 16 - 20 > 20 
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KNOWLEDGE OF GENERIC MEDICINES 
 
Select an option from 1 – 5 based on how strongly you agree or disagree with the statement: 








 5 4 3 2 1 
Generic medicines are a copy of original 
medicines 
     
Generic medicines are interchangeable with 
original medicines 
     
Generic medicines are therapeutically 
equivalent to  
original medicines 
     
Generic medicines must be in the same 
dosage form (such as tablet, capsule) as 
original medicines 
     
Generic medicines are less safe than original 
medicines 
     
Only those generic medicines which are made 
by some local reputable manufacturers are 
safe 
     
Generic medicines are manufactured after the 
patent expiry of originator/innovator 
     
Original medicines are of a better quality than 
generic medicines 
     
Original medicines are required to meet 
higher safety standards than generic medicine 
     
Original medicines produce fewer side effects 
than generic medicines 
     
Low-priced medicines are as effective as 
high-priced medicines 
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PERCEPTIONS OF GENERIC MEDICINES 
 
Select an option from 1 -5 based on how strongly you agree or disagree with the statement: 
5=strongly agree, 4=Agree, 3=neither disagree nor agree, 2=Disagree, 1=Agree. 
 
 5 4 3 2 1 
I believe that locally manufactured 
medicines are more affordable than 
original medicines 
     
I believe that locally manufactured 
medicines are of the same effectiveness 
as original medicines 
     
I view generic medicines as being of a 
poorer quality than original medicines 
     
I think generic medicines produce more 
side effects than original medicines 
     
I believe low-cost medicines are as safe 
as high-cost medicines 
     
I believe that multinational products are 
of a better quality than locally produced 
products 
     
I believe that the local companies in 
South Africa are not following Good 
Manufacturing Practice (GMP) 
guidelines as well as multinationals 
     
I view few local companies as reputable 
generic medicine manufacturers 
     
I believe that pharmacists should be 
educated more about prices of medicines 
     
I believe that generic medicines are only 
meant for the poor 
     
I think that confidence should be built in 
the patient about the low-cost brand 
     
Wider use of generic drugs will mean 
that less money will be used for research 
and development of new 
pharmaceuticals.  
 








Tick the appropriate block. More than 1 option may be chosen 
 
COST TO CUSTOMER  
HAVING NO OTHER CHOICE  
CUSTOMER PREFERENCE  
AVAILABILITY OF STOCK  
CUSTOMER APPEARANCE  
COST EFFECTIVENESS  
PROVEN BIOEQUIVELANCE  
MEDICAL SCHEME REQUIREMENT  
DO NOT RECOMMEND GENERICS  
 
 

















     
 
 






WHAT ARE THE POSSIBLE PROBLEMS THAT YOU HAVE NOTICED 




















HOW DO YOU NORMALLY FIND OUT ABOUT THE AVAILABILITY OF 
A GENERIC ALTERNATIVE TO AN ORIGINAL DRUG? PLEASE 




If Other, Please specify 
___________________________________________________________________________
___________________________________________________________________________  
DRUG MANUFACTURER REPRESENTATIVES  
DRUG WHOLESALER  
MEDICAL JOURNALS  
DRUG COMPANY WRITTEN INFORMATION  
FROM PHARMACIST/ COLLEAGUES/PEERS  
FROM PATIENTS  
FROM DOCTORS  
INFORMATIONAL LITERATURE ( NEWSLETTERS, ARTICLES)  
FROM INTERNET/WEBSITES/E-MAILS  
FROM MEETINGS/CONFERENCES  
OTHER  
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APPENDIX B: ETHICAL APPROVAL LETTER 
 
